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Summary 
Despite major efforts in prevention and treatment, the HIV epidemic remains a global 
problem affecting millions of people. Understanding the basic mechanisms governing HIV 
transmission and pathogenesis is a prerequisite to develop new therapeutic strategies. 
One of the organs most affected by HIV is the gut. The intestinal mucosa is densely populated 
with CD4+ T-cells and macrophages, the main HIV target cells. The aim of this thesis was to 
define the role of the gut for HIV transmission and pathogenesis in vivo. To this end, we used 
mice reconstituted with human, hematopoietic stem cells, so called humanized mice. 
Humanized mice develop a lymphoid system of human origin, and therefore, can be infected 
with HIV, a human-specific virus. 
First, we evaluated the potential of humanized mice as a model for studying rectal HIV 
transmission. Injection of HIV reliably led to infection of mice, but rectal challenge rarely 
initiated HIV infection. In contrast to most other lymphoid organs in the mice, the gut 
contained almost no human cells. This disproportionately low intestinal engraftment probably 
is the reason for the low HIV transmission rates we observed. Even when we increased the 
HIV infection risk, for example by inducing colitis, rectal HIV transmission was infrequent. 
Thus, humanized mice are unsuitable for investigating rectal HIV transmission. 
The putative disadvantage of lacking intestinal engraftment though enabled us to elucidate a 
key mechanism of HIV pathogenesis. In chronically HIV-infected patients, depletion of 
intestinal CD4+ T-cells and increased intestinal permeability is correlated with disease 
progression. Comparing uninfected and HIV-infected mice with and without intestinal barrier 
dysfunction, we identified underlying mechanisms linking intestinal barrier function and HIV 
pathogenesis. HIV infection induced translocation of intestinal bacteria to systemic 
compartments. Uninfected animals controlled this translocation by increasing the phagocytic 
capacity of macrophages. In HIV-infected mice, macrophage phagocytosis was inadequate 
leading to uncontrolled translocation, activation of T-cells, increased HIV replication and T-
cell loss. Macrophage dysfunction seems to determine HIV pathogenesis. 
In conclusion, our results underscore the importance of the gut as a HIV target organ. 
Intestinal CD4+ cells are a prerequisite for rectal HIV transmission; after mucosal HIV 
exposure systemic infection is not possible without local spreading. In chronic infection, 
disturbed intestinal barrier function has negative consequences for the whole body. 
Modulating the control of bacterial translocation might be a therapeutic approach.  
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Zusammenfassung 
Die globale HIV Epidemie bleibt trotz ständiger Verbesserung von Therapie und Prävention 
ein schwerwiegendes Problem, das Millionen von Menschen betrifft. Das Verständnis von 
HIV-Transmission und Pathogenese ist eine Grundvoraussetzung um neue therapeutische 
Ansätze zu finden. 
Eines der am meisten von HIV beeinträchtigten Organe ist der Darm. Die intestinale 
Schleimhaut ist dicht gepackt mit CD4+ T-Zellen und Makrophagen, den Hauptzielzellen von 
HIV. In der aktuellen Arbeit charakterisierten wir die Rolle des Darmes für die HIV Infektion. 
Dazu benutzten wir humanisierte Mäuse als in vivo HIV-Modell. Normale Mäuse sind 
resistent gegenüber HIV, humanisierte Mäuse hingegen haben dank einer 
Stammzelltransplantation humane Immunzellen und können mit HIV infiziert werden. 
Zuerst evaluierten wir die Eignung humanisierter Mäuse als Modell rektaler HIV-
Transmission. Die Mäuse konnten zuverlässig infiziert werden, wenn wir HIV injizierten, 
rektale Exposition jedoch führte selten zur Infektion. Der Darm enthielt fast keine humanen 
Zellen, im Gegensatz zu anderen Organen. Dies verunmöglichte rektale HIV-Transmission, 
sogar in Situationen mit hohem Risiko, wie zum Beispiel in Mäusen mit einer entzündeten 
Darmschleimhaut. Daher sind humanisierte Mäuse schlecht geeignet um rektale HIV-
Transmission zu studieren. 
Dieser vermeintliche Nachteil fehlender Immunzellen im Darm erlaubte uns aber einen der 
wichtigsten HIV-Krankheitsmechanismen zu studieren. Indem wir die humanisierten Mäuse 
mit HIV infizierten oder die Barrierefunktion des Darmes manipulierten, konnten wir die 
Situation in chronisch HIV-infizierten Patienten simulieren. Diese Patienten haben auch ein 
Defizit von CD4+ T-Zellen im Darm. In den humanisierten Mäusen konnten wir nun zeigen, 
dass aufgrund der HIV-Infektion Darmbakterien in den Körper eindringen und nicht mehr von 
Makrophagen beseitig werden. Diese Makrophagenfehlfunktion erlaubt eine Aktivierung des 
Immunsystems, die mit vermehrter HIV-Replikation und einem verschlimmerten 
Krankheitsverlauf einhergeht. Makrophagenfehlfunktion ist eine wichtige Facette des HIV-
bedingten Immunschadens. 
Zusammenfassend unterstreichen unsere Resultate die wichtige Rolle des Darmes als HIV-
Zielorgon. Beeinflussung von Zellen im Darm oder Zellen, die die systemischen 
Konsequenzen einer gestörten Darmfunktion regulieren, ist ein vielversprechender 
therapeutischer Ansatz. 
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Chapter 1 introduces the role of the intestinal mucosa in HIV infection. Chapter 2 explores 
experimental models of rectal HIV transmission. In chapter 3 the relationships between 
mucosal dysfunction and HIV pathogenesis are summarized. Chapter 4 examines the 
systemic consequences of intestinal barrier breakdown in HIV infection. 
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1. Introduction 
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1.1 The intestinal mucosa as a target organ for HIV 
HIV infection of intestinal lymphocytes 
Already in the beginning of the HIV pandemic, it was suspected that the gut associated 
lymphoid tissue (GALT) plays a central role for the spreading of HIV. In 1981, physicians in 
San Francisco noted a clustering of immunodeficiency and opportunistic infections in 
beforehand healthy young men1. Since most of them were homosexual, sexual transmission of 
an infectious agent via rectal exposure seemed likely2,3. Subsequently, a novel retrovirus was 
identified as the causative agent4,5 and named human immunodeficiency virus (HIV). Indeed, 
HIV is often transmitted via mucosal surfaces and unprotected rectal intercourse carries a high 
transmission risk6. Thus, rectal HIV exposure is considered a major risk factor for both 
homosexual and heterosexual HIV transmission7. Even if infection is established by a 
different route, for example by intravenous HIV exposure, the GALT is a site of extensive 
viral replication8. The GALT provides an optimal environment for HIV to establish and 
maintain an infection due to its unique cellular composition. HIV mainly infects CD4+ 
lymphocytes and macrophages9, and both these cell types are abundantly present in the 
intestinal mucosa10.  
 
Figure 1: The GALT is densely populated with HIV target cells. The intestinal immune system consists of 
priming (isolated lymphoid follicles and Peyer’s patches) and effector sites (lamina propria). Both contain 
numerous lymphocytes and macrophages that can be infected by HIV.  BC = B cell, DC = dendritic cell, GC = 
germinal center, IEL = intraepithelial lymphocyte, MO = macrophage, PC = plasma cell 
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 Figure 2: Three main genes influence the 
structure and function of HIV. The HIV genome 
consists of ssRNA and encodes for three genes 
common in all retroviruses and for some accessory 
genes specific for HIV. Pol encodes the viral 
enzymes, gag the structural protein p24, and env the 
surface glycoproteins gp41 and gp120. 
 
A large part of all the body’s lymphocytes reside in the gut11, either in organized lymphoid 
structures- such as isolated lymphoid follicles or Peyer’s patches, or dispersed inbetween 
intestinal epithelial cells and the underlying lamina propria (Fig.1). Therefore, the GALT is a 
formidable target organ for HIV. In particular, HIV’s cellular tropism12 explains the 
widespread infection of GALT lymphocytes13. CD4 is the main receptor for glycoprotein (gp) 
12014 (Figure 2), the viral envelope molecule that mediates entry of HIV into host cells. 
Additionally, the virus needs a co-receptor, either CCR515 or CXCR416, for stable attachment 
and fusion of the viral with the cellular membrane (Figure 3). Most of the virions isolated 
from patients use CCR517; they are so called R5 viruses. Only late in disease course, in about 
half of all patients, X4 viruses arise18. Reasons for this class switch are not clear yet, but in 
general it is assumed that the virus adapts to the depletion of CD4+CCR5+ target cells and 
thereby acquires the ability to use CXCR4 as co-receptor19. 
CD4, CCR5 and CXCR4 are expressed on T-helper lymphocytes and most monocytic cells20. 
The exact expression pattern though depends on maturation and activation state of the cells. In 
the GALT many lymphocytes are in a partially activated, memory state21 and therefore 
express CD4 and CCR522. HIV easily infects such cells. In acute infection for instance up to 
60% of all GALT CD4+ T cells harbor HIV DNA23. Some of these cells produce HIV; some 
of them are in a resting state and only harbor HIV DNA without active HIV transcription. 
HIV is a retrovirus24; this means that it can establish a latent reservoir by integrating its 
reverse transcribed genome into the host DNA25. In resting cells, the virus can hide 
undetected by the immune system for a long time26. Then, upon activation of the cell viral 
RNA is transcribed and new virions are produced (Figure 3). Such a productive infection 
quickly kills lymphocytes27, but macrophages in particular can produce virus for several days 
or even weeks28. Thus, the GALT with its huge pool of CD4+CCR5+ lymphocytes and 
macrophages is optimally suited for HIV to spread, multiply, and remain latently integrated. 
Thus, interactions of HIV with GALT cells have an impact on acute and chronic infection and 
heavily influence the outcome of HIV disease on an individual and on a population level. 
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Figure 3: The HIV life cycle depends on binding of the virus to CD4 and a co-receptor. HIV gp120 binds to 
CD4 and CCR5 or CXCR4. After fusion of the viral membrane with the cell membrane, the viral RNA is 
uncoated, reverse transcribed and transported to the cell nucleus. The viral genome is integrated into the host 
DNA and serves as a template for the production of new viral RNA and proteins. 
 
The rectal mucosa as a site of entry for HIV 
In most cases, HIV’s route of entry is via the mucosa, vaginal, rectal or oral29. Transmission 
by direct contact with blood- i.e. via i.v. drug use, via injuries or medical procedures- is much 
rarer, although it carries a higher per-contact risk30,31. By this direct route, HIV needs not to 
overcome the mucosal barrier to reach its target cells. The vaginal epithelium with its many 
layers is quite hard for the virus to overcome. The rectal epithelium, in comparison, is 
composed of a single layer of columnar epithelial cells and thus, rectal HIV exposure has a 
relatively high transmission risk compared to other transmission routes32. Penetration of the 
intestinal mucosa can happen by different mechanisms. HIV may enter directly through 
breaches in the epithelial layer, it may penetrate by transcytosis33, for example mediated by M 
cells34, or dendritic cells, which sample antigen from the intestinal lumen, may take up 
virus35. This last mechanisms is particularly important, since intestinal dendritic cells express 
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high levels of DC-SIGN, a DC specific C-type lectin, that can bind HIV gp120 and transmit 
bound virus to T-cells36. Certainly, CD4+ T-cells can also be infected directly by free HIV 
virions, but cell-associated transmission seems to be more efficient in vitro37. So far, it is not 
clear which mode of transmission- i.e. cell-free or cell-associated- predominates in vivo. In 
cats, transmission rates were equal in animals inoculated mucosally with cell-free or cell-
associated feline immunodeficiency virus38. In humans however, the detailed processes 
leading to rectal HIV transmission are difficult to study. The availability of human intestinal 
tissue samples is limited, even more so if samples from patients with acute HIV infection are 
needed. 
The risk of acquiring HIV by rectal exposure varies. It increases with the viral load of the 
transmitter39, or due to local inflammation40,41, and traumatic lesions in the exposed. In 
general though, rectal HIV transmission is relatively ineffective, with an average per-contact 
risk of about one percent42,43. Establishing a new infection via the mucosal route seems to be 
hard for the virus. This notion is further supported by data about the viral diversity in acutely 
infected patients. Normally HIV is a very diverse virus with many different viral clones 
present in a single patient44. The reverse transcriptase, that transcribes the viral RNA genome 
into DNA, is error prone45 and recombination between different HIV quasispecies occurs 
frequently46. Therefore, HIV virions isolated from a single chronically infected patient are 
very heterogeneous. In acute infection, however, only one or a few viral clones are present in 
a single patient, indicating that a “bottleneck” exists47. This bottleneck limits transmission and 
establishment of a new infection to certain viral clones48. Viral and host factors influencing 
this bottleneck remain to be determined and further knowledge is needed to design new 
preventive strategies 
 
Dysfunction of the intestinal mucosa in chronic HIV infection 
HIV infection is characterized by a massive depletion of intestinal CD4+ T-cells49. CD4+ T-
cells have important functions for regulating mucosal immune defenses. Particularly in the 
gut, where a multitude of mostly harmless microbes reside, CD4+ T-cells contribute to a fine 
tuned balance between tolerance and defense50. Loss of this protective function might be 
crucial in determining HIV pathogenesis51. HIV’s disease course is quite heterogeneous from 
patient to patient52 and some of these differences may be due to differences in GALT function 
and subsequent changes that may influence HIV replication and T-cell loss51 (Figure 4). 
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Many patients with chronic HIV infection show signs of enteropathy- diarrhea in the absence 
of a typical infectious cause53. Active viral replication has detrimental effects on intestinal 
barrier function; both viral components54 and cytokines55 produced in response to HIV 
infection influence the epithelial layer and this results in increased permeability. 
Translocation of bacterial products from the gut is associated with HIV disease progression in 
chronically HIV-infected patients56. Functional data about bacterial translocation and HIV 
pathogenesis are rather scarce. Therefore, direct causative links between intestinal barrier 
dysfunction and HIV pathogenesis are not completely understood yet. 
Restoring mucosal barrier function and immune control might prevent HIV pathogenesis. 
Results from studies in monkeys support this hypothesis. African monkeys infected with 
simian immunodeficiency virus (SIV) remain healthy despite depletion of intestinal CD4+ T-
cells57. This species evolved to depend less on CD4+ T-cells for controlling intestinal barrier 
function58 and to rapidly limit the pro-inflammatory response to SIV infection59. Eliciting 
such an “African monkey phenotype” in humans might slow down or stop the development of 
immunodeficiency in HIV-infected patients. But, understanding the exact mechanisms leading 
to intestinal CD4+ T-cell depletion and subsequent disease progression in HIV-infected 
humans is a prerequisite to develop such new therapeutic approaches. 
 
CD4+ T-cells
Figure 4. Variances in HIV 
progression can be explained 
by activation. After the initial 
uproar of acute infection, 
CD4+ T-cell loss and HIV 
replication gradually progress. 
Progression rates correlate with 
T-cell activation levels, which 
in turn are linked to bacterial 
translocation. Depending on 
activation status, a patient’s 
time to developing AIDS varies 
from weeks to years. 
T-cell activation
Viral load
Time (weeks to years)
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1.2 Aims of the thesis 
Establishing a small animal model of rectal HIV transmission 
HIV research has long been hampered by the lack of a small animal model that mirrors HIV 
infection in humans60 and permits to study questions such as vaginal or rectal transmission. 
Availability and adaptability of human intestinal tissue explants are limited. Conventional 
laboratory animals, such as rats or mice, are resistant to HIV infection61. Otherwise, SIV 
infection of rhesus macaques can be used as a model of pathogenic retroviral infection62. 
Although SIV is closely related to HIV, not all results from monkey studies can be directly 
translated to the human situation. Furthermore, ethical and financial factors foreclose large 
scale experiments in rhesus macaques. A small animal HIV model would greatly facilitate 
HIV research in vivo. 
Transplanting immunodeficient mice with human lymphocytes is a well established strategy 
to generate HIV permissive mice (Figure 4). Though HIV infection is possible in these mice, 
depending on the specific model system considerable disadvantages exist. For instance, mice 
receiving peripheral blood lymphocytes (hu PBL SCID)63 are easy to generate but human 
engraftment is limited to a relatively short time, not all cell-lineages are present, and almost 
all lymphocytes exhibit an activated phenotype due to the xenogenic environment. To achieve 
longer lasting engraftment fetal organs such as thymus or liver (hu thy/li SCID) can be used 
for transplantation64. But this approach rarely leads to systemic engraftment of human cells, 
therefore HIV infection remains confined to the transplanted organoid. Combining the 
transplantation of fetal tissues and hematopoietic stem cells generates bone 
marrow/liver/thymus (BLT) mice that show systemic human engraftment65 and even are 
susceptible to mucosal HIV transmission66. But, a model that does not require the 
transplantation of fetal organs would be much simpler and allow the generation of larger 
cohorts of animals. 
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SCID PBMC
NOD SCID fetal thymus/ liver
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Figure 4: Different HIV mouse models. Several 
strains of immunodeficient mice are used for 
transplantation of human T-cells that then can be 
infected with HIV. Transplanting differentiated 
lymphocytes from peripheral blood (PBL) 
generates animals for short term experiments. By 
using either fetal organs or hematopoietic stem 
cells, longer lasting human engraftment can be 
achieved. Properties of each model depend on 
mouse strain and transplantation protocols. 
 
Therefore, we decided to explore the potential of so called humanized mice as a model for 
rectal HIV infection. Newborn, immunodeficient mice show good engraftment of human cells 
after transplantation of hematopoietic stem cells. Human T-, B- and myeloid cells develop de 
novo and human cells can be found in many organs67. Thus, humanized mice support 
disseminated, long-lasting HIV replication68. In the current work, we evaluated human 
engraftment in the intestinal tract of humanized mice, determined HIV transmission rates after 
rectal inoculation, and assessed the impact intestinal inflammation on HIV transmission 
(Chapter 2: Rectal HIV transmission in humanized mice). 
 
Investigating the pathogenic potential of bacterial translocation in HIV infection 
The natural course of HIV disease is a progressive destruction of the immune system 
eventually leading to the acquired immunodeficiency syndrome (AIDS)69. The hallmark of 
this immunodeficiency is the progressive loss of CD4 T-cells27. The mechanisms leading to 
CD4 T-cells loss in chronic HIV infection remain poorly understood. During the chronic 
phase, only small fraction of all CD4 T-cells actively produce HIV70, indicating that only a 
minority of cells may be killed by direct viral cytopathicity. This led to the notion that most of 
the cells that die are in fact not infected71. Currently two mechanisms are held responsible for 
T cell death: one proposes chronic immune activation and activation induced cell death 
(AICD) as the driving force behind HIV pathogenesis; the other implies that released viral 
proteins such as gp120, Tat, Vpu or Nef induce killing of bystander cells27. 
There is growing evidence in support of the chronic immune activation theory. Up-regulation 
of the cell surface activation marker CD38 on CD8 T cells is the best prognostic factor for 
disease progression72. Furthermore, in monkey studies a good correlation was found between 
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immune activation and disease development73. Briefly, African monkeys infected with simian 
immunodeficiency virus (SIV) do not show immune activation and do not progress to AIDS. 
In contrast, SIV infection of Asian monkeys leads to immune activation and disease 
progression. However, the causes of immune activation are poorly defined. 
A potential mechanism causing immune activation is invasion of microbial products from the 
gut. Circulating lipopolysaccharide (LPS), a marker of microbial translocation from the 
gastrointestinal tract, is increased in chronically HIV infected individuals and correlates with 
immune activation levels56. However, the question remains if this microbial translocation is 
the cause or rather an effect of the immune disturbance seen in HIV infection (reviewed in 
Chapter 3: Pathogenesis mechanisms of bacterial translocation in HIV infection). 
So far most studies investigating bacterial translocation in HIV infection have only shown 
correlative data from infected humans or monkeys. Consistent findings have been that in 
chronic infection plasma LPS is increased and that these values correlate with immune 
activation, which in turn is the best marker to predict disesease progression. Up to now no 
animal model was available to study the causative relations between bacterial translocation 
and HIV pathogenesis. Our unique model of HIV infected humanized mice allows to 
investigate these connections in a targeted and well controlled manner. In the current work, 
we elucidated the relationships between intestinal permeability, bacterial translocation, 
clearance of translocated bacterial products, and HIV pathogenesis (Chapter 4: Bacterial 
translocation and immune activation in HIV infected humanized mice). 
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show low intestinal engraftment and are resistant to rectal HIV 
transmission 
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Gehre1,3, Stephan Regenass4, Thomas Brunner5, Roberto F Speck1* 
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Rectal transmission is one of the main routes of infection by human immunodeficiency 
virus type-1 (HIV). To efficiently study transmission mechanisms and prevention 
strategies, a small animal model permissive to rectal HIV transmission is mandatory. 
We tested the susceptibility of RAG2-/-?c-/- mice transplanted with human cord blood 
hematopoietic stem cells to rectal HIV infection. We rectally exposed these humanized 
mice to cell-free and cell-associated HIV. All mice remained HIV negative as assessed by 
plasma viral load. The same mice infected intraperitoneally showed high levels of HIV 
replication. In the gut-associated lymphatic tissue, we found disproportionately smaller 
numbers of human cells than in other lymphoid organs. This finding may explain the 
observed resistance to rectal HIV transmission. To increase the numbers of local HIV 
target cells and the likelihood of HIV transmission, we treated mice with different pro-
inflammatory stimuli: local application of interleukin 1?, addition of seminal plasma to 
the inoculum or colitis induction with dextran sodium sulphate. These procedures 
attracted some human leukocytes, but the transmission rate was still very low. The 
humanized mice showed low human engraftment in the intestinal tract, seem to be 
resistant to rectal HIV transmission, and thus are an unsuitable model for this 
application. 
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Introduction 
Millions of people worldwide are infected with HIV. Despite improved treatment strategies 
and efforts in prevention, no end of the pandemic is in view. HIV transmission occurs mostly 
by sexual intercourse via mucosal routes74; rectal intercourse carries an especially high risk6 
and thus is considered one of the major risk factors for both homosexual and heterosexual 
HIV transmission7. For the rational design of prevention methods such as microbicides, we 
need detailed knowledge of HIV transmission and in particular the early steps of HIV 
infection.  
HIV research has long been hampered by the lack of a small animal model that recapitulates 
HIV infection in humans and permits to study vaginal or rectal transmission. Studies with 
larger animals can provide important clues to understand transmission and improve the design 
of trials in humans. Non-human primates and less frequently cats have been used62,75, but 
have significant problems, such as low availability, high costs and species differences. HIV is 
a human-specific virus, and non-human primates and felines are resistant to HIV. Thus, either 
simian, simian-human chimeric or feline immunodeficiency viruses have to be used as an 
approximation for HIV. 
Immunodeficient mice transplanted with human cells as an animal model for HIV disease 
have numerous advantages and some shortfalls. Cohort size can be increased significantly, 
providing more robust statistical validity to experiments. Mice are less costly and labor 
intensive than larger animals, and notably, they are susceptible to HIV. Severe combined 
immunodeficient (SCID) mice transplanted with either human fetal thymus/liver (Thy/Li) or 
human peripheral blood leukocytes (PBL)76 are well-established models. The rate of mucosal 
HIV transmission in hu-PBL-SCID mice is low and variable77 and renders this mouse model 
unsuitable for preclinical studies of microbicides. Significantly, the SCID-hu Thy/Li mouse 
has never been evaluated for mucosal transmission since human cells are mostly found in the 
transplanted organ and peripheral engraftment is low78. 
Recently, we and others reported humanized mice as a promising new model for HIV 
research66,68,79-83. In these models, transplantation of human hematopoietic CD34+ cells into 
immunodeficient mice leads to the development of all human lymphoid lineages and the 
repopulation of lymphoid organs with human cells. These models differ according to the 
mouse strains used (i.e., NOD/SCID, NOG/SCID or RAG2-/-c?-/- mice) and the origins of 
human hematopoietic cells transplanted (i.e., CD34+ from fetal liver or cord blood). 
Previously, we showed sustained and disseminated HIV replication in RAG2-/-c?-/- mice 
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transplanted with cord blood CD34+ cells after intraperitoneal injection of HIV68. So far, only 
two studies investigating HIV infection in humanized mice showed successful HIV infection 
by the rectal route66,84. In these studies, human transplants were obtained from fetal tissue. 
Aside from any ethical considerations, fetal tissue is not as easily and widely available as cord 
blood. Furthermore, one study used bone marrow/liver/thymus (BLT) mice, which receive a 
thymic organ transplant before irradiation and reconstitution with fetal liver derived 
hematopoietic stem cells.  
In the current study, we examined mucosal HIV transmission in RAG2-/-c?-/- mice transplanted 
with cord blood-derived CD34+ cells. We characterized the engraftment of human cells into 
the gastrointestinal tract of these humanized mice and determined their susceptibility to rectal 
HIV transmission. We challenged mice with cell-free and cell-associated HIV since their 
relative contributions are not known. Overall, rectal transmission rates were low in all groups 
of humanized mice, independently of pre-infection treatment and inoculation protocols. 
20 
 Material and methods 
Generation of humanized mice 
Mice were reconstituted as described67,68. Briefly, newborn RAG2-/-c?-/- mice were irradiated 
with 2x2 Gy. CD34+ cells were isolated from cord blood with immunomagnetic beads 
(Milteny Biotec), and 150,000 to 400,000 cells (246,000 ± 60,000) were transplanted into 
each mouse. Fetal liver derived CD34+ cells were a kind gift from R. Akkina (Colorado State 
University). Eight to 12 weeks after transplantation, the levels of blood engraftment were 
determined by flow cytometry of peripheral blood mononuclear cells (PBMCs) stained for the 
human panleukocyte marker CD45 in all mice (mean human cells/live cells 11.56 ± 10.9%). 
Liver, bone marrow, and spleen engraftment levels were also analyzed in 14 mice. All 
experiments were approved and conducted according to local guidelines and laws. 
Tissue characterization  
Formalin-fixed tissue sections from liver and large intestines were stained with hematoxylin 
and eosin (H&E) or for markers for human CD45 (clones PD7/26 and 2B11, Dako), CD4 
(clone 1F6, Novacostra) and CD68 (clone GG-M1, Dako). To control for non-specific 
staining, tissue from untransplanted mice was stained as well. Human CD45+ cells were 
counted at a magnification of 200x at 10 randomly chosen locations per organ and mouse. In 
interleukin (IL)-1?-treated mice, cell numbers were evaluated separately for the 1.5 cm most 
proximal to the anus. 
Lymphocytes from the small and large intestines were isolated (gut-associated lymphatic 
tissue or GALT)85 sequentially from the intraepithelial and lamina propria compartments of 
three mice with a mean blood engraftment of 13.7%. Briefly, intestines were opened 
longitudinally, cut in pieces and washed five times with cold PBS, 2% FCS. Then the 
epithelial layer was dissociated by stirring tissue pieces for 30 minutes in PBS, 2% FCS, 2 
mM EDTA and 2 mM dithiothreitol at 37° C. Supernatants were collected and filtered 
through 70- and 40-?m cell strainers. Cells were washed twice and kept on ice until analysis 
by flow cytometry. The remaining tissue was incubated for 15 minutes in cold RPMI, 10% 
FCS, then stirred at 37° C in RPMI, 5% FCS, 100 U/ml collagenase IV and 10 U/ml DNAse I 
(both from Sigma) to extract lamina propria lymphocytes. After 30 and 60 minutes of 
digestion, supernatants were collected, and fresh digestion medium was added to the tissue 
pieces after the first collection step. Supernatants were treated as mentioned above.  
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Pro-inflammatory treatment with interleukin 1? 
Mice were anaesthetized with Ketamine and Rompun (50 and 8 mg/kg, respectively), and 250 
units of recombinant human interleukin (IL)-1? (Invitrogen) in 25 ?l of PBS were applied 
intrarectally with a pipette 24 hours before infection. The mice were suspended head down for 
1 minute. 
Colitis induction 
Colitis was induced by cyclic treatment with 1% (w/v) dextran sodium sulfate (DSS) 
(molecular weight 40,000, MP Biomedicals) added to the drinking water for 4 days, followed 
by 7 days of normal drinking water86,87. At the end of the third cycle, colitis was verified in 
formalin-fixed tissue sections, or the mice were used for HIV challenges. H&E sections of 
DSS-treated and untreated mice were scored for epithelial changes and inflammatory 
infiltration as described88. 
HIV infections 
For cell-associated HIV infections, the CCR5-tropic HIV strain YU-2 was used, for cell-free 
HIV infections either YU-2, JR-CSF (CCR5-tropic), NL4-3 (CXCR-4 tropic) or 89.6 (dual 
tropic)68 were used. Cell-associated HIV was prepared by infecting CD8+ T cell-depleted 
PBMCs pooled from three donors. PBMC first were stimulated with 2 ?g/ml 
phytohemagglutinin (PHA) for 3 days, then spinoculated with YU-2 at an MOI of 0.1 for 2 
hours, at 1200g and 25° C. After the washing, the cells were returned to culture without 
further addition of PHA. Four days after spinoculation, infection rates were measured by 
intracellular p24 staining (6.5–12.5% positive), and viability was controlled by Trypan blue 
staining (>90%). Cells were washed twice and suspended either in PBS or seminal plasma. 
Cell-free virus stock was used undiluted or mixed 1:1 with seminal plasma. Mice received 
rectally cell-free stock virus at a dose of 2x105 (YU-2), 5x103 (JR-CSF), 1x104 (89.6) or 2x105 
(NL4-3) TCID50 or 2x106 infected PBMCs. Anesthesia and inoculation were performed as 
described above. 20 ?l of the respective inoculum were applied per mouse, except for 
mixtures of cell-free HIV and seminal plasma, which were given in volumes of 40 ?l. Mice 
infected intraperitoneally received 200 ?l of cell-free virus, corresponding to 2x106 TCID50. 
Plasma viral loads were measured by RT-PCR (Amplicor, Roche) at 4 to 6 weeks and again at 
8–12 weeks post infection (p.i.). Detection limit was 800 copies/ml. 
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Tracking of rectally instilled labeled cells 
PBMC were stimulated with PHA, mock spinoculated and cultured as above. Cells were 
labeled with carboxy fluorescein succinimidyl ester (CFSE), washed and mixed in 20 ?l of 
either PBS or seminal plasma and applied rectally at 2x106 cells per mouse. After 2, 4, and 6 
hours, the mice were euthanized. Intestinal tissue was removed and snap-frozen. Cryosections 
were ethanol fixed and counterstained with DAPI. 
Statistical analysis 
GraphPad Prism 5.01 was used for statistical analysis. Data were analyzed by two-tailed t-
tests, all unpaired except for naive mice, in which cell numbers from liver and rectum from 
the same mouse were paired. 
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 Results 
Low engraftment efficiency of human cells in the intestinal tract of humanized 
mice 
GALT contributes substantially to the lymphoid system overall, and thus, its detailed 
characterization is mandatory for estimating its contribution in immunological questions. In 
humans, GALT contains abundant numbers of CD4+ T cells, the main target cells of HIV. 
However, little is known about GALT in humanized mice.  
We examined the engraftment of human cells into the gut of RAG2-/-c?-/- mice transplanted 
with CD34+ cells from human cord blood. Tissue sections of the rectum and the liver of 14 
humanized mice were fixed with formalin and stained for the human panleukocyte marker 
CD45. Isolated cells from the liver, bone marrow, blood and spleen were analyzed for CD45+ 
cells by flow cytometry. From three additional mice, we isolated GALT cells: intraepithelial 
lymphocytes and lamina propria lymphocytes from the small (SI IEL and SI LPL) and large 
intestines (LI IEL and LI LPL). We included three wild-type mice as positive controls for the 
isolation procedure of the GALT. 
Human cell numbers in tissue sections of rectum were significantly lower than in those from 
liver (Fig. 1A and B). The same pattern was seen in flow-cytometric analysis: engraftment 
levels in the intestines ranged between 0.001 and 0.1%, whereas in other organs examined, 
they were up to 800 times higher (Fig. 1D). The cellular composition and the protocols to 
isolate cells differ substantially, according to tissue. Thus, comparisons between relative cell 
numbers in organs are difficult to interpret. However, GALT lymphocytes from wild-type 
mice exhibit large numbers of CD4+ cells in the LI LPL cell fractions (Fig. 1C). Isolation of 
CD4+ cells from wild-type mice shows that the lack of human cells in the GALT from 
humanized mice is not due to technical problems.  
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 Figure 1: Engraftment levels were disproportionately lower in the gut of humanized mice than in other 
tissues. Mice were analyzed for engraftment with human leukocytes by measuring cells positive for the human 
panleukocyte marker CD45. Tissue sections of rectum and liver of 14 mice were stained for CD45 (A, arrows 
indicate positive cells), and cells were counted per square centimeter (B, mean, SD, p=0.0094). From three mice, 
lymphocytes from the intraepithelial space (IEL) and the lamina propria (LPL) from the large and small intestine 
(LI and SI) were isolated. Cells from the liver, spleen, bone marrow, and blood were isolated from 14 mice and 
analyzed by flow cytometry for proportions of human CD45-positive cells. Despite high engraftment levels in 
the blood, almost no human cells were detectable in the lamina propria of the large intestines, where the majority 
of CD4+ cells were found in wild-type mice (C). Overall, intestinal engraftment was low, whereas in other 
organs, percentages of human cells were high (D). Bars represent 200?m. 
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Naive humanized mice are resistant to rectal HIV transmission 
In body fluids, HIV occurs as free virions (cell-free) or inside of infected cells (cell-associated 
virus). The extent of cell-free or cell-associated HIV in rectal transmission is unknown. 
Infected cells could act as “Trojan horses” to release large numbers of virions upon invasion 
of mucosal tissue.  
We exposed five naive (untreated) humanized mice to cell-free HIV YU-2 at a dose of 2x105 
TCID50 per mouse and nine mice to cell-associated HIV YU-2 (i.e., 2x106 HIV-infected 
PBMC, range of HIV-positive PBMC as verified by intracellular p24 staining: 6.5–12.5%) per 
mouse. After 4 weeks, all mice were negative for plasma viral load by PCR. We then injected 
four of the same mice with cell-free HIV YU-2 intraperitoneally. These four mice then 
showed high viral loads, while the remaining rectally exposed mice still were negative 8 
weeks after inoculation (Fig. 2B). We included three mice with no detectable human 
engraftment in the blood to verify whether repopulation with rectally instilled HIV-infected 
cells would result in HIV infection. These also tested negative for HIV. 
It is possible, that the origin of human stem cells used to generate humanized mice could 
influence intestinal engraftment efficiency and subsequently rectal HIV infection rates. 
Therefore we reconstituted nine newborn mice of the same litter either with cord blood 
derived or fetal liver derived CD34+ cells and 12 weeks later exposed them rectally to cell-
free HIV YU-2 as described above. One of the five mice which received cord blood cells and 
none of the four mice reconstituted with liver derived cells tested HIV positive one month 
after challenge (Fig.2B). 
The efficiency of rectal transmission varies between different HIV strains. To exclude that the 
low rectal transmission rates we observed, were a specific feature of YU-2, we tested three 
other viral strains: JR-CSF, 89.6 and NL4-3. Three groups of six mice received cell-free HIV 
rectally at a dose of 5x103 (JR-CSF), 1x104 (89.6) or 2x105 (NL4-3) TCID50 per mouse. Of the 
18 mice challenged none showed a detectable plasma viral load 4 and 8 weeks after challenge. 
We also prepared PBMC for mock infections. These cells were labeled with CFSE before 
rectal instillation to track their location subsequent to rectal instillation (Fig. 2A). Only a few 
single cells had invaded the mucosa after 6 hours; most of the inoculum probably was 
excreted (Fig. 2C). 
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 Figure 2: Rectal HIV transmission in naive mice was rare. Naive (untreated) humanized mice were exposed 
rectally to cell-free (cf) or cell-associated (ca) HIV, and plasma viral load was measured 4 to 8 weeks later 
(Amplicor Roche). Cell-associated HIV was prepared following a three-step protocol: CD8+-depleted PBMCs 
from three donors were pooled and PHA stimulated, then spinoculated and cultured for 4 more days (A). Nine 
mice were inoculated rectally with infected PBMC; five mice were inoculated with cell-free HIV. Plasma viral 
load was negative in all mice, four of the same mice were then inoculated by intraperitoneal injection, and all 
became HIV positive (B, squares). Additional mice were reconstituted in parallel either with fetal-liver derived 
(B, triangles, n=4) or with cord blood-derived CD34+ cells (B, circles, n=5) and challenged rectally with cell-free 
HIV. One of the mice receiving cord blood cells tested HIV positive. A cell migration assay was performed with 
mock spinoculated cells. CFSE-labeled cells were applied rectally to three mice. In cryosections, a few single 
invading leukocytes (arrows) were detected (C). 
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While infection rates after i.p. injection of HIV were high, we rarely detected HIV 
transmission after rectal exposure, either to cell-free or cell-associated HIV. Our finding that 
instilled cells rarely cross the rectal mucosa can explain the resistance of humanized mice to 
cell-associated HIV. 
Rectal application of IL-1? leads to low levels of infiltration with human cells 
IL-1? is a potent pro-inflammatory cytokine and mediates leukocyte chemotaxis. We 
speculated that local pre-treatment with IL-1? would attract human lymphoid cells to the 
rectal mucosa and increase HIV transmission. In some experiments, we added human seminal 
plasma to the inoculums. Seminal plasma may have chemotactic potential89 and may enhance 
attachment of HIV to target cells90. However, semen has many pro- and anti-viral factors91, 
and its exact role in HIV transmission is still unknown.  
We treated three humanized mice rectally with 250 units of IL-1?. After 24 hours, we 
detected inflammatory changes, such as vessel dilatation and cell infiltration, at the site of 
application (Fig. 3A). Most of the infiltrating cells were murine, but significantly more human 
cells were found than in untreated mice (Fig. 3A and B). We detected both human CD4- and 
CD68-positive cells in the rectal mucosa at the site of IL-1? application (data not shown). 
This observation confirms that IL-1? attracted some human CD4 cells and macrophages, 
potential HIV targets, to the rectal mucosa of humanized mice. 
We also pre-treated mice with IL-1? and challenged them 24 hours later with cell-associated 
HIV or cell-free HIV, with or without seminal plasma, at the same doses as the naive mice. 
Transmission rates were still low (Fig. 3C). Of 12 mice inoculated with cell-free or cell-
associated HIV mixed with seminal protein, none developed viremia, while one of 5 mice 
inoculated with cell-free virus developed viremia. 
Additionally, we tracked CFSE-labeled cells after rectal application with the IL-1? pre-
treatment scheme and addition of seminal plasma to the inoculum. The results were similar to 
those described for naive mice: only a few single cells crossed the rectal epithelial layer and 
penetrated into the mucosa (data not shown). 
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Figure 3: Rectal HIV transmission in mice treated with local pro-inflammatory stimuli. We treated three 
humanized mice rectally with 250 IU IL-1? and checked for inflammation and infiltration with human CD45+ 
cells 24 hours later (A, arrows indicate positive cells). Rectal mucosa proximal to application-site showed an 
increase in human cells, whereas cell numbers distal to application-site were as low as in untreated mice (B, 
mean, SD, p=0.0033). Mice treated the same way were then exposed to cell-associated (ca) or cell-free (cf) HIV. 
In some experiments, seminal plasma (SP) was added to the inoculum. Plasma viral load was measured. One 
mouse showed viral replication 4 weeks after HIV challenge (C), and the same results were seen 8 weeks post 
infection (not shown). Bars represent 200?m. 
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Humanized mice are highly susceptible to DSS-induced colitis 
Concomitant sexually transmitted diseases are important risk factors for HIV transmission. In 
particular, mucosal inflammation increases susceptibility to infection by disrupting the 
epithelial lining and changing numbers and phenotype of local target cells41. We tried to 
reproduce this situation in our humanized mice by inducing a chronic colitis with DSS87. 
So far, DSS colitis has not been studied in humanized mice. Prior studies established that 
Rag2-/- mice are susceptible to acute92 and chronic colitis93 in the DSS model. In a first 
experiment, humanized mice treated with 3% DSS in normal drinking water for 4 days lost 
?20% of starting weight and showed severe clinical symptoms. Therefore, we treated the 
humanized mice with three cycles of 1% DSS interrupted by 7 days of normal drinking water 
and then monitored weight and state of health daily (Fig. 4A). Mice tolerated this reduced 
dose well and suffered only from minimal weight loss. One week after the last DSS 
administration, we analyzed the large intestines of three mice histologically: tissue sections 
showed inflammatory changes with alteration of the epithelial layer and infiltration of 
leukocytes, partly of human origin (Fig. 4B–D). Notably, human cell numbers in the mucosa 
seen by staining for human CD45 were significantly higher in DSS treated animals than in 
animals that received normal drinking water. 
To assess the impact of rectal inflammation on HIV transmission rate, we challenged mice 
with cell-associated HIV 7 days after the last DSS administration. Unexpectedly, 24 hours 
after inoculation, all mice were severely affected, and some did not recover. Mortality was 
50% in the first week after infection. The remaining animals recovered completely, and HIV 
RNA levels were measured 4 and 8 weeks after HIV inoculation. No infection was detectable 
in all three mice that completed the trial. We conclude that, despite mucosal inflammation, 
transmission of cell-associated HIV is improbable in humanized mice. 
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Figure 4: DSS induces colitis in humanized mice. Twelve humanized mice received three cycles of 1% DSS in 
normal drinking water. This treatment induced moderate weight changes (A) due to colitis induction. Colitis was 
confirmed by histological scoring of tissue sections of three mice (B, p=0.0008). DSS treatment induced cellular 
infiltration consisting mostly of murine cells since only a fraction of cells was positive for human CD45 (C, 
positive cells indicated by black arrows). However, in comparison to untreated mice, human cell numbers were 
increased after DSS treatment (D, p=0.0005). DSS-treated mice were then inoculated with HIV (red arrow in A). 
Bars represent 200?m. 
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Discussion 
Humanized mice are a promising model for large-scale studies of HIV transmission, and their 
characterization is critical to future studies. Our study describes human engraftment in GALT 
of cord blood CD34+ cell-transplanted RAG2-/-c?-/- mice. We show that, in this particular 
model, human cell numbers in the GALT are lower than in other lymphatic organs and 
increase only moderately after pro-inflammatory treatment. Furthermore, we examined the 
susceptibility of these humanized mice to rectal HIV transmission and found a very small rate 
of rectal HIV transmission. Only 2 of 56 challenged mice became HIV positive. Thus, this 
model may have limited value for the study of rectal HIV transmission. 
Two other studies showed successful rectal infections of humanized mice66,84 with 
transmission-rates of 6/7 and 11/14, respectively. Sun et al.66 used NOD/SCID mice 
transplanted with fetal liver and thymus and later reconstituted with liver-derived CD34+ cells 
(BLT mice). Berges et al.84 transplanted RAG2-/-c?-/- mice with CD34+ cells from fetal liver. 
Thus, a major difference is that we used cord blood–derived cells. So far it is not clear which 
source of hematopoietic stem cells is optimal for the generation of humanized mice. In vitro, 
the colony-forming efficiency of CD34+ cells derived from fetal liver is higher than that of 
cord blood CD34+ cells94. However, in vivo cord blood–derived hematopoietic stem cells 
produced four times more mature human leukocytes than liver-derived cells, when the same 
number of stem cells was transplanted into adult NOD/SCID mice95. When telomere length is 
used as a measure of replicative capacity of hematopoietic stem cells from fetal liver and cord 
blood, the differences are minimal96, indicating that both are suitable for generating 
humanized mice. However, it is not known to what extent the origin of lymphoid cells may be 
critical for repopulation of the intestines with human cells. Different expression of cell 
adhesion molecules97 could influence homing behavior and subsequent repopulation of 
lymphoid organs. That, in turn, may explain the lower infection rates we observed in our 
model using cord blood–derived cells for transplantation. But when we reconstituted mice in 
parallel either with cord blood-derived or with fetal liver-derived cells, rectal HIV 
transmission was not more efficient in the mice which had received liver-derived cells.  
Apart from the different origin of CD34+ cells, Berges et al. and we used similar models 
based on mice with the same genetic background. However, Berges et al. reported higher 
engraftment levels than the ones we detected. They found blood engraftment levels of almost 
90%, whereas the mice used in our study had a mean engraftment of about 11%. But these 
values cannot be directly compared. Berges et al. measured percentage of human cells in 
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blood lymphocytes; we measured percentage of human cells in all blood leukocytes, which 
include murine cells as well. Since RAG2-/-c?-/- mice have no B, T and NK cells of their own, 
obviously all lymphocytes detected in humanized mice should be of human origin. In our 
cohort of mice transplanted with liver-derived cells, we saw no differences in engraftment 
levels compared to engraftment levels in littermates transplanted with cord blood-derived 
cells. This indicates that the origin of the stem cells probably has no major impact, at least in 
our hands, and that other factors are influencing HIV transmission rates in humanized mice. 
The intestinal microflora plays important roles in GALT development: intestinal bacteria 
influence the migration pattern of lymphocytes into mucosal sites; in germ-free animals, 
intestinal lymphocyte numbers are drastically decreased98. Certainly, the microflora in the gut 
of mice from different genetic backgrounds and from different animal facilities varies and 
could influence human engraftment in GALT and subsequently HIV transmission 
susceptibility. Besides of potential differences in gut microflora, especially in BLT mice, 
gastrointestinal engraftment appears to be significantly better than the GALT engraftment we 
obtained in RAG2-/-c?-/- mice. BLT mice have the advantage of a human thymic tissue 
transplant, which could facilitate T cell development.  
In our humanized mouse model, T-lymphocyte development occurs in the anlage of the 
murine thymus, which is almost completely repopulated with human cells. Nonetheless, the 
stroma of this thymus is of murine origin and may have unknown disadvantageous effects on 
overall lymphoid development. Furthermore, to generate BLT mice, the NOD/SCID mouse 
strain was used. In contrast to RAG2-/-c?-/- mice, NOD/SCID mice do not have mutations or 
loss of ?c, the common gamma chain in receptors of multiple cytokines, including IL-7. 
Signaling through the IL-7 receptor is essential for formation of the Peyer’s patches anlagen99, 
and humanized mice lacking this important feature may have more difficulties in repopulating 
the GALT than mice that have Peyer’s patches anlagen. 
To enrich for human cells of lymphoid origin in the rectal mucosa in our humanized mouse 
model, we induced local inflammation. Mucosal inflammation as seen in sexually transmitted 
diseases is a risk factor for HIV acquisition be increasing numbers of HIV target cells and 
disturbing epithelial integrity41. We treated humanized mice with Il-1? rectally 24 hours 
before HIV challenge. In untreated mice no infections could be seen, in treated mice 1/17 
showed a detectable plasma viral load. Immune histochemical analysis of Il-1?-treated 
uninfected mice suggests that, despite an inflammatory response and cell infiltration, human 
cell numbers were probably still too low to establish infection. It is believed that HIV first 
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infects a local founder population in the lamina propria of the mucosal tissue and amplifies 
there before systemic seeding and dissemination of the infection100. In our model, local 
expansion of infection is difficult with only a few human cells present in the lamina propria. 
We only observed disseminated infection when mice were injected intraperitoneally with 
HIV, and the mucosal amplification step was not needed. 
To attract human cells more efficiently to the GALT, we treated humanized mice with DSS, a 
compound widely used in murine models of inflammatory bowel disease. Repeated treatment 
with DSS leads to a chronic colitis with infiltration of lymphocytes and macrophages86. After 
three cycles of DSS treatment of humanized mice, we also saw infiltration of human cells into 
the rectal mucosa. Moreover, we confirmed colitis induction by following weight changes and 
finally by histological scoring of rectal tissue. Mice tolerated treatment well up to 1 week 
after the last DSS administration when a rapid decline in health occurred and half of the mice 
had to be euthanized. The HIV challenge could be a reason for the observed health decline. 
However, all mice were similarly affected, even surviving mice, which remained HIV 
negative. Notably, in non-DSS-treated mice, the same HIV challenge never elicited any 
symptoms. We therefore conclude that the DSS chronic colitis model is not suitable for 
rendering humanized mice permissive to rectal challenges with HIV. 
It is still unknown whether cell-free or cell-associated HIV is preferably transmitted. To 
develop microbicides or vaccines, it is essential to know whether protection is needed against 
free virions, infected cells, or both. In simian and feline models, both cell-free and cell-
associated virus transmission can be observed with different efficiencies, depending on 
experimental design38,101,102. Results from studies in humans are conflicting: both free virions 
and infected cells are detected in cervicovaginal fluid103 and semen104. In cervical explants, 
which frequently are used for pre-clinical microbicide testing, cell-free and cell-associated 
HIV are infectious105. Here, we detected only minimal transmigration of rectally applied 
mononuclear cells into the mucosa both in untreated and Il-1?-treated humanized mice. 
Further infection experiments with cell-associated HIV confirmed this observation. None of 
the mice exposed to HIV-infected PBMC showed systemic viral replication, not even mice 
that had DSS colitis. Thus, cell-associated HIV transmission is, at least in our model, not 
more efficient than cell-free HIV transmission. 
HIV strains with selective co-receptor use or even more subtle viral variants may differ in 
their ability to establish infection by the mucosal route. In humans CCR5-tropic HIV is 
transmitted preferably over CXCR4-tropic HIV106 and even in the group of CCR5 viruses, 
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potential for transmission is diverse. Patients during acute infection show a more homogenous 
viral population, whereas patients in the chronic phase harbor many distinct variants107,108, 
indicating that only some of the viral variants in the transmitter are passed on. However, the 
characteristics of HIV variants preferentially transmitted are unknown so far. The CCR5-
tropic HIV variant YU-2, which we used in our study for rectal challenge, was first isolated 
from neural tissue of a child suffering from AIDS109. There is some uncertainty whether it is 
easily transmitted by the mucosal route or not. In any case, YU-2 replicates well in humanized 
mice and establishes disseminated infection after intraperitoneal injection68, and the three 
other HIV strains we tested in this study, were not more efficient in rectal HIV transmission. 
The other two studies66,84 showing mucosal HIV transmission in humanized mice showed that 
the mice were permissive to CXCR4-tropic HIV infection by the rectal route. However, Sun 
et al. challenged mice with HIV after mechanical disruption of the epithelial layer. It remains 
unknown whether the CXCR4-tropic viral strain used would have been transmitted otherwise. 
So far, we do not know whether the same bottleneck seen in humans for mucosal HIV 
transmission exists in humanized mice. 
In conclusion, our data indicate that GALT reconstitution in RAG2-/-c?-/- mice transplanted 
with CD34+ cells from cord blood is low and these mice seem to be quite resistant to rectal 
HIV transmission, even in an inflammatory setting. Their value to study measures preventing 
mucosal HIV transmission probably is limited. Further efforts are needed to clarify which 
mouse strain and transplantation protocol are best suited to generate the optimal humanized 
mouse. 
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Why and how HIV makes people sick is highly debated. Recent evidence implicates 
heightened immune activation due to breakdown of the gastrointestinal barrier as a 
determining factor of lentiviral pathogenesis. HIV-mediated loss of Th17 cells from the 
gut-associated lymphoid tissue (GALT) impairs mucosal integrity and innate defense 
mechanisms against gut microbes. Translocation of microbial products from the gut, in 
turn, correlates with increased immune activation in chronic HIV infection and may 
further damage the immune system by increasing viral and activation-induced T-cell 
death, by reducing T-cell reconstitution due to tissue scarring, and by impairing the 
function of other cell types, such as ?? T cells and epithelial cells. Maintaining a healthy 
GALT may be the key to reducing the pathogenic potential of HIV. 
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Introduction 
HIV infection is characterized by a progressive immunodeficiency, which is reflected in a 
steady decline of CD4+ T cells. Disease progression varies considerably from patient to 
patient. Some develop the acquired immunodeficiency syndrome (AIDS) after a few months; 
others remain healthy for decades. Such a disparity also exists in monkeys of distinct species 
infected with simian immunodeficiency virus (SIV). SIV infection of African monkeys, the 
natural hosts for SIV, does not result in simian AIDS, but SIV infection of most Asian 
monkeys rapidly progresses to AIDS110. Remarkably, despite 25 years of HIV and SIV 
research, the reasons for these differences in disease outcome are only partially understood. 
To design new treatment approaches, including vaccination or eradication strategies, we need 
to understand the basis for these disparities.  
Immune dysfunction and disease onset cannot be explained solely by the direct cytopathic 
effect of the virus. Other factors have been implicated in T-cell loss, such as the killing of 
infected cells by cytotoxic T cells, bystander death of uninfected cells due to HIV products, 
and T-cell dysfunction and death due to heightened levels of immune activation73. A 
hyperactive immune state with high T-cell turnover, polyclonal activation of B cells, and 
elevated pro-inflammatory cytokines is characteristic of HIV infection73. In fact, the 
activation status of CD8+ T cells is one of the best predictors of disease progression72. While 
the association of immune activation and HIV infection is well known, its causes are only 
partially understood.  
A recent model links disturbance of the gut-associated lymphoid tissue (GALT) to immune 
activation and lentiviral disease progression51. The GALT is one of the primary organs 
affected by HIV and SIV, and GALT lymphocytes are the primary target cells of HIV during 
mucosal transmission. After rectal exposure, they are the first immune cells that encounter 
HIV. For infections by different routes, they form a large pool of HIV target cells, in which 
HIV efficiently spreads and replicates. Later on, during chronic HIV infection, loss of GALT 
integrity may have a major impact on AIDS pathogenesis111. Briefly, during the chronic phase 
of infection, elevated levels of microbial products are found in the systemic circulation, and 
these levels correlate with immune activation and disease state. Initial studies looking at 
interactions of lentiviruses with the GALT focused mainly on numbers of infected and dying 
T cells. Recently, studies have proposed cellular and molecular mechanisms that clarify the 
intricate role of GALT in HIV pathogenesis. Here we will review these studies and relate their 
findings to lentiviral disease progression. 
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Profound depletion of GALT lymphocytes occurs during acute lentiviral infection 
The CD4+ T-cell count in the blood is a commonly used clinical marker for monitoring 
progression rate in HIV infection. In acute HIV infection, blood CD4+ T-cell numbers may 
decline sharply, but as soon as an antiviral immune response is established, blood CD4+ T 
cells have the potential to recover. Subsequently, during chronic HIV infection, blood CD4+ 
T-cell counts decline slowly, but this loss can be partially reversed by successful antiretroviral 
treatment. However, T cells in the GALT display entirely different kinetics: in SIV-infected 
macaques and in HIV-infected humans, CD4+ T cells of the lamina propria are rapidly and 
profoundly depleted in the first days after infection, and their numbers remain low throughout 
the course of disease8,112,113. Even after years of antiretroviral therapy, this loss is only 
partially reversible in most patients114,115. Thus, lymphocyte depletion in the GALT is a 
distinct feature of lentiviral infection. 
The pronounced loss of GALT lymphocytes probably occurs because the majority of newly 
transmitted HIV strains use CCR5 as a co-receptor for cell-entry20. A high percentage of 
CD4+ T cells in the intestinal effector sites are CCR5 positive memory cells, and thus, GALT 
lymphocytes are ideal viral targets. In contrast, many T cells in blood and lymph nodes are 
naive and hence CCR5 negative116. During acute SIV infection, up to 60% of all memory 
CD4+ T cells in the jejunum harbor HIV DNA23, suggesting that direct viral cytopathic 
effects cause the massive loss of CD4+ T cells during acute infection. Furthermore, high 
levels of Fas-mediated apoptosis of infected and uninfected CD4+ T cells occurs during peak 
viremia117. Direct viral killing and bystander death of uninfected cells wipe out most of the 
CD4+ memory cell population in the GALT. 
When the loss of GALT lymphocytes was first discovered, it appeared plausible that this 
defect in mucosal immune surveillance would have dire consequences for the whole immune 
system and would influence disease progression. Surprisingly, however, SIV depletes lamina 
propria T cells in all monkey species, irrespective of whether they will develop simian AIDS 
or not. Natural SIV hosts, such as sooty mangabeys and African green monkeys, do not 
progress to AIDS despite high viral loads, but rhesus macaques infected with the same SIV 
strain show blood CD4+ T-cell loss and disease progression, closely resembling HIV 
pathogenesis in humans110. In both the pathogenic and non-pathogenic SIV model, GALT 
CD4+ T cells are lost at similar rates during acute infection57,118. At later times, however, the 
GALT can be partially restored in the non-pathogenic models. These observations indicate 
that acute intestinal CD4+ T-cell loss is a basic feature of lentiviral infections but is not 
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predictive of later disease outcome. Low numbers of GALT lymphocytes per se do not make 
animals or humans sick; additional factors are important for the pathogenic potential of HIV. 
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In chronic lentiviral infection, circulating microbial products are associated with 
immune activation 
Differences in pathogenic and non-pathogenic SIV models become more apparent when 
GALT function, rather than simple lymphocyte numbers, is considered. The GALT prevents 
microbial invasions from the intestinal lumen. In chronic lentiviral infections, this function 
seems to be disturbed, and more microbial products are found in the systemic circulation. 
Brenchely et al.119 measured plasma levels of lipopolysaccharide (LPS), a component of 
gram-negative bacterial cell walls, as an indicator of microbial translocation from the gut. 
They found higher plasma LPS levels in chronically HIV-infected patients than in healthy 
subjects. Notably, a similar LPS increase was observed in the pathogenic SIV rhesus macaque 
model. In contrast, in the non-pathogenic SIV sooty mangabey model, LPS levels were low, 
irrespective of SIV status. Thus, in SIV-infected sooty mangabeys, GALT immune function 
appears to be sufficient to prevent increases of bacterial products in the systemic circulation 
despite intestinal CD4+ T-cell depletion. 
To further elucidate the connection between clinical outcome and microbial translocation, 
plasma LPS levels were examined in defined subsets of patients. For example, Hunt et al.120 
verified a finding from Brenchely et al.119: HIV-infected elite controllers—patients with 
undetectable viral loads without antiretroviral treatment—have LPS levels similar to patients 
with higher viral loads. At first glance, these data might indicate that no connection between 
plasma LPS and disease outcome exists. However, Hunt et al. showed that plasma LPS in 
elite controllers correlated with immune activation, which was associated with lower CD4+ 
T-cell counts. This finding suggests that, in elite controllers, immune activation is detrimental 
and leads to CD4+ T-cell loss, despite suppressed plasma viral load, and that bacterial 
translocation may be the activating factor. 
Marchetti et al.121 investigated bacterial translocation in patients on highly active 
antiretroviral therapy (HAART). All patients on HAART had lower plasma levels of LPS 
than untreated control patients. As defined by blood CD4+ T-cell reconstitution, therapy 
success was associated with even lower LPS levels. Patients who did not show T-cell 
recovery despite suppressed HIV RNA had more bacterial translocation as quantified by 
plasma LPS than patients who responded immunologically and virologically to HAART. This 
means that in both groups with suppressed viral loads—either in elite controllers or in 
HAART treated patients—low-level microbial translocation still occurs and seems to be 
associated with lower CD4+ T-cell counts. 
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In support of the link between bacterial translocation and HIV pathogenesis, Ancuta et al.122 
found higher plasma LPS levels in patients with HIV-associated dementia than in HIV-
positive patients without neurocognitive impairment. They proposed LPS-mediated monocyte 
activation and trafficking to the brain as the underlying mechanism of this association 
between LPS and dementia. As supporting evidence, they showed up-regulation of activation 
markers on monocytes and increases of soluble CD14, IL-6, and CCL2 in the plasma of HIV-
infected patients. 
To further investigate the effects of bacterial translocation on immune activation, Gregson et 
al.123 compared plasma LPS levels in HIV-infected individuals to HIV-negative patients with 
active colitis, either colitis ulcerosa or Morbus Crohn. All groups had similarly elevated LPS 
levels. However, colitis usually shows a fluctuating course: the gastrointestinal barrier, in fact, 
is only affected during an inflammatory phase but is relatively intact between flare-ups. In 
contrast, HIV-infected patients seem to experience constant bacterial translocation and 
immune activation.  
However, factors other than bacterial translocation are thought to contribute to sustained 
immune activation. In particular, Gregson et al. reported that the activated phenotype of NK 
cells seen in their cohort of HIV-positive patients was linked to the plasma viral load and not 
to plasma LPS. Strikingly, the colitis patients, which had LPS levels as high as the HIV-
positive patients, showed only low numbers of activated CD8+ T cells, indicating that high 
levels of plasma LPS alone do not cause activation of CD8+ T cells. 
A study in patients undergoing interruption of antiretroviral therapy124 supports the notion that 
CD8+ T-cell activation not only depends on plasma LPS. In the first 6 weeks after stopping 
HAART, LPS levels remained unchanged, whereas percentages of activated blood CD8+ T 
cells increased. Only later did plasma LPS levels rise, but still no association with activated 
CD8+ T cells was detected, perhaps because the study examined a relatively small population. 
Interestingly, the delayed onset of LPS increase after treatment interruption mirrors the initial 
findings of Brenchely et al.119, which also showed that, for LPS to increase, some time of 
sustained viral replication was required. Plasma LPS levels were similar in patients with acute 
HIV infection and in healthy control subjects. A possible explanation is that, initially, 
systemically circulating LPS can be cleared, but over time, this function is impaired. The 
treatment interruption study showed a negative correlation between changes of plasma LPS 
levels and endotoxin core antibodies (EndoCAb) in the early phase, when plasma LPS levels 
are controlled. Later on, this correlation is lost. They claimed that, initially, LPS is cleared by 
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EndoCAb, and EndoCAb levels therefore decrease. After some time, clearance is no longer 
effective, due either to excessive microbial translocation or to inadequate B-cell function. 
In conclusion, there is universal agreement that heightened levels of circulating bacterial 
products correlate in general with immune activation in pathogenic lentiviral infections (Table 
1). However, careful interpretation is needed when deducing the mechanistic links between 
these events. A direct causative relation has not been established between heightened LPS 
levels and HIV disease progression. In an alternative explanation, microbial translocation may 
be an epiphenomenon of an activated and dysfunctional immune system. 
Also what is the deficit in the GALT resulting in bacterial translocation? Recent studies 
propose a mechanism linking depletion of a subset of GALT effector site lymphocytes, 
namely Th17 cells, with breakdown of the gastrointestinal barrier. Such a link is a first step in 
explaining the relationships between HIV infection and GALT dysfunction. 
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Table 1. Bacterial translocation in lentiviral infections. 
Study Subjects Parameters Results 
Ancuta et 
al.122 
HIV in humans: progressors 
with or without HIV-associated 
dementia 
LPS 
sCD14, LBP, 
EndoCAb, IL-6, 
CCL2 
CD16+, CD69+, or 
CCR5+ monocytes 
higher LPS levels in patients with 
dementia, association between 
monocyte activation, LPS and 
dementia 
HIV in humans: negative, 
acute/early, chronic, AIDS 
higher LPS levels in chronic 
n, correlation with immune 
ion 
infectio
activat
HIV in humans: negative, before 
and after HAART 
LPS dec
no
rease under HAART, but 
 normalisation 
HIV in humans: negative, 
controllers, progressors 
higher LPS levels in controllers 
compared to uninfected subjects, 
o significant difference to 
progressors 
n
SIV in rhesus macaques: 
negative, positive, positive 
treated with antibiotics 
LPS increase after SIV infection in 
RMs, reduction under antibiotics 
Brenchley et 
al.119 
SIV in sooty mangabeys: 
negative, positive 
LPS 
sCD14, LBP, 
EndoCAb 
LPS reactivity of 
monocytes ex vivo 
plasma IFN? 
CD8+ HLA DR+ 
CD38+ T-cells 
low LPS levels in both groups of 
SMs 
Gregson et 
al.123 
HIV in humans: negative, 
untreated/viremic, HAART 
Colitis: active Crohn’s disease or 
colitis ulcerosa 
LPS 
CD8+ HLA DR+ 
CD38+ T-cells 
NK cell activation 
LPS reactivity of NK 
cells ex vivo 
higher LPS levels in HIV infected, 
irrespective of HAART 
no difference of LPS levels 
between HIV infected and colitis 
patients 
NK and CD8 T-cell activation in 
HIV infected patients, not in colitis 
patients 
Hunt et al.120 HIV in humans: negative, 
controllers, progressors 
LPS 
CD8+ HLA DR+ 
CD38+ T-cells 
higher LPS levels in controllers 
compared to uninfected subjects, 
no significant difference to 
progressors, correlation between 
activated CD8 T cells and LPS in 
controllers 
Marchetti et 
al.121 
HIV in humans: 
untreated/advanced, 
HAART/full responders, 
HAART/immunological non 
responders 
LPS, bacterial 
16sRNA CD4 and 
CD8 Ki67+ 
treatment reduced LPS levels 
overall, but immunological non 
responders had higher levels than 
full responders 
Papasavvas 
et al.124 
HIV in humans: HAART before 
and after short/long time 
treatment interruption 
LPS 
sCD14, LBP, 
EndoCAb 
CD8+ CD38+ T-cells 
no LPS increase after short time 
treatment interruption, but already 
increase of CD8+ T-cell activation 
after long time treatment 
interruption LPS increase 
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Th17 cells help are essential for the integrity of the gastrointestinal barrier 
Th17 cells are important for intestinal homeostasis (reviewed in125). Briefly, this subset of 
CD4+ T cells is characterized by the production of IL-17 in response to stimulation, but they 
also secrete other cytokines, including TNF-?, IL-1, IL-6, IL-21, and IL-22. Their strong pro-
inflammatory properties are both beneficial and harmful. Initial animal studies identified 
Th17 cells as important mediators of autoimmune disease and tissue damage126,127, yet with 
their ability to recruit neutrophils128, they also are important for controlling infections by 
bacteria and fungi129-134. Furthermore, Th17 cells are involved in epithelial regeneration135. 
They stimulate production of defensins and mucin136,137, and they induce the expression of 
claudins138, which are components of epithelial tight junctions. Finally, IL-22, an important 
Th17 cytokine, increases the production of LPS binding protein (LBP) in the liver139. 
Considering the massive CD4+ T-cell depletion in the lamina propria after HIV infection, it is 
reasonable to assume that Th17 cells are also depleted by HIV. And with their multiple 
functions in controlling epithelial integrity and microbial invasion, their loss likely affects the 
integrity of the gastrointestinal barrier. 
While Th17 cells are permissive to HIV in vitro, they do not appear to be the preferential 
targets of HIV140 nor of SIV141. Infection rates are similar in all CD4+ T cells, irrespective of 
Th17 or Th1 differentiation. Nevertheless, in acutely SIV-infected rhesus macaques, the 
intestinal Th17 responses seem to be afflicted more than the Th1 response. Checchinato et 
al.141 found that the percentage of IL-17-producing cells, as related to all intestinal CD4+ T 
cells, was much lower, whereas the percentage of IFN-? producing cells was much greater 
than in healthy animals. Relative numbers, however, do not take into account the massive 
reduction of absolute CD4+ T-cell numbers in the gut during acute SIV infection. Even 
though relative numbers of Th1 cells may be increased, the absolute numbers are still strongly 
reduced. We can only poorly judge the importance of relative differences between Th17 and 
Th1 responses in light of the overall loss of lymphocytes.  
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 Figure 1. HIV infection depletes lymphocytes, including Th17 cells, from the GALT effector sites. Th17 cells 
are essential in maintaining an intact gastrointestinal barrier against gut microbes by producing cytokines that are 
essential for epithelial regeneration and neutrophil recruitment. In HIV-positive individuals, circulating 
microbial products can be detected, and these levels correlate with immune activation. 
 
Brenchley et al.140 further investigated the effects of HIV infection on T-cell subsets at 
different mucosal surfaces and compared T-cell responses in lung and gut. In contrast to 
results from bronchoalveolar lavage samples, they found a preferential depletion of IL-17-
producing CD4+ T cells in the gut of HIV-infected humans. This result indicates that HIV 
infection especially reduces the intestinal Th17 function. In contrast to reports in humans, in 
SIV-infected sooty mangabeys the relative numbers of IL-17+ CD4+ T cells in the gut are 
similar to those in uninfected animals. The authors linked this intact Th17 function in SIV-
infected sooty mangabeys with their non-pathogenic phenotype. Again, one should be careful 
in interpreting relative cell numbers from the gut, because of the overall depletion of CD4+ T 
cells. 
Still, the data from both these studies suggest that the intestinal Th17 response is diminished 
during lentiviral infection, probably due to depletion or dysfunction of these cells. What are 
47 
now the consequences of an impaired Th17 response in the gut? Raffatellu et al.142 addressed 
this question in an elegant study using a gut ligation model in rhesus macaques to study 
Salmonella translocation. Individual intestinal loops from the same animal are either mock 
inoculated or exposed to Salmonella, and immune responses then can be quantified. Intestinal 
Salmonella inoculation induced a strong mucosal Th17 response in this model. This Th17 
response, however, was blunted when the rhesus macaques were chronically SIV infected. 
Consequently, SIV infected rhesus macaques had a greater degree of Salmonella translocation 
to mesenteric lymph nodes than SIV-negative monkeys. One could argue that this effect of the 
SIV infection on immune control of Salmonella translocation may not be Th17 specific but 
rather is due to overall GALT depletion. But Raffatellu et al. confirmed their data in mice 
with a targeted defect in the IL-17 receptor. Due to abrogated IL-17 signaling, these mice had 
less production of other IL-17 dependent cytokines upon gastrointestinal Salmonella 
inoculation, they recruited less neutrophils to the mucosa, and they were unable to control 
Salmonella translocation. The data from Raffatellu et al. corroborate the current view that 
HIV infection results in a loss of the intestinal Th17 response and that this affects the integrity 
of the gastrointestinal barrier.  
In conclusion, these studies propose a model in which HIV/SIV-mediated Th17 depletion 
from GALT effector sites impairs the gastrointestinal barrier. This, in turn, leads to 
translocation of intestinal microbes or microbial products, which then contribute to immune 
activation (Fig. 1). However, we must be aware that no definitive experimental proof links 
Th17 dysfunction and elevated LPS levels. Increased intestinal Salmonella invasion after SIV 
infection is an intriguing hint but not the same as continuous translocation of harmless 
commensal bacteria. In Cecchinato et al.141, for example, no correlation between LPS levels 
and GALT Th17 cell numbers was found in SIV-infected macaques. Nevertheless, Th17 cells 
probably are important in overall immunodeficiency. Recently, a defect in Th17 
differentiation in patients with autosomal dominant hyper Ig-E syndrome143 was identified. 
Hyper-Ig-E syndrome is characterized by Candida infections, recurring pneumonia, skin 
abscesses, and lymphomas—a clinical picture reminiscent of AIDS. However, no data exist 
on the integrity of the gastrointestinal barrier and bacterial translocation in these patients. 
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A disturbed gastrointestinal barrier may have negative effects on the immune 
system 
While circulating microbial products correlate well with activation markers on immune cells, 
the exact connection between these two phenomena is not clear. Does immune activation 
render the immune system so dysfunctional that it can no longer control bacterial 
translocation, or do the circulating bacteria and bacterial components activate the immune 
system and thereby contribute to the progressive immunodeficiency observed in HIV? Both 
possibilities likely co-exist, leading to a vicious circle in which one factor triggers the other 
one. In any case, sustained immune activation has negative effects on T-cell function and 
survival. For one, sustained activation provides a large pool of activated CD4+ T cells, which 
are optimal viral targets since HIV more efficiently infects and replicates in activated CD4+ T 
cells144. However, in most of the above studies, no positive association between plasma viral 
load and LPS was found119,124. This is not surprising, since many other factors besides overall 
activation status can influence viral load (e.g., HIV-specific immune responses, chemokine 
levels, and viral fitness). 
In addition to providing a continuous reservoir of optimally activated HIV target cells, 
microbial products may initiate activation-induced cell death. An innovative study by 
Bourgeois et al.145 in mice showed that naive CD4+ T cells are especially affected by 
activation-induced cell death from gut antigens. While investigating peripheral T-cell 
dynamics after thymic ablation, they found a substantial decay in naive CD4+ T cells, while 
CD8+ T-cell counts remained relatively stable. As the cause of CD4+ T-cell activation and 
subsequent activation-induced death of naive cells, they identified translocation of microbial 
products from the gut. Indeed, the mice had higher levels of LBP, an acute phase protein 
produced in the liver after exposure to LPS. Notably, in transfer experiments, they established 
that those CD4+ T cells reactive to gut microbes and involved in intestinal inflammation were 
lost specifically. Induction of intestinal inflammation by transfer of T cells reactive to gut 
microbes is an established tool in colitis research146. Naive CD4+ T cells depleted of 
CD25high cells are transferred into immunodeficient mice, there they proliferate and respond 
to intestinal antigens. Bourgeois et al.145 found that CD4+ T cells from donor mice with 
bacterial translocation could no longer induce colitis in the recipient mice. Because of the 
antigen recognition and activation mechanisms in CD4+ T cells, these cells may be especially 
prone to effects from microbial translocation. Microbial products circulate in the extracellular 
compartment and are taken up by antigen-presenting cells for processing and presentation on 
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MHC class II molecules. Thereby, CD4+ T cells (i.e., those cells recognizing antigen in the 
context of MHC II) but not CD8+ T cells are activated and die. 
HIV infection likely influences other immune cells in the GALT. For example, T-regulatory 
cells (Tregs) are also affected. Tregs are abundant in the intestinal mucosa and are involved in 
maintaining a healthy balance between tolerance and immune control of gut microbes. Highly 
viremic SIV-infected macaques have more mucosal Tregs than animals with low viral 
loads147. These numerous Tregs may contribute to a less efficient SIV-specific immune 
response and consecutively to increased SIV loads. However, this hypothesis is controversial. 
Another study showed that inhibiting Treg function with a blocking antibody to CTLA-4 
increased SIV replication, particularly at mucosal sites148. This study suggests that Tregs are 
protective by reducing immune activation and viral replication. Thus, increased Treg numbers 
in highly viremic macaques may represent a negative regulatory feedback mechanism. 
The GALT contains many cell types besides classical CD4+ T cells (e.g., plasma cells, 
dendritic cells, monocytes, or ?? T cells). Little is known about their fates during chronic 
lentiviral infection. Some studies suggest that they may be essential for limiting microbial 
translocation. In addition to depletion of Th17 cells, Brenchley et al.140 also noted loss of 
myelomonocytic cells in the GALT of HIV-infected individuals. These myelomonocytic cells, 
which include granulocytes, macrophages, and dendritic cells, are essential for killing and 
phagocytosis of gut microbes, and for orchestrating an adaptive immune response. Another 
hint for the involvement of additional GALT cells in controlling microbial translocation 
comes from one of the non-pathogenic SIV models: Sooty mangabeys, which do not show 
prolonged systemic LPS increases despite GALT CD4+ T-cell depletion, have astoundingly 
high numbers of ?? T cells. ?? T cells build an interface between innate and adaptive 
immunity and are essential for immune function at mucosal surfaces149. Therefore, they may 
have a protective effect on integrity of the intestinal barrier and may limit bacterial 
translocation. Compared to humans, sooty mangabeys have higher numbers of ?? T cells, and 
their ?? T-cell response to bacterial antigens is even enhanced150 after SIV infection. In 
contrast, in HIV-infected humans ?? T-cell counts are lower, and the cells are anergic to 
stimulation with mycobacterial antigens151. 
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 Figure 2. Microbial translocation and ensuing immune activation can damage the immune system and contribute 
to HIV pathogenesis. By increasing numbers of activated cells, which are preferentially infected, microbial 
translocation can increase viral replication. Furthermore, activated cells are prone to activation-induced cell 
death, and immune reconstitution is limited due to fibrosis of the lymphatic tissue. Other immune cells, such as 
macrophages or ?? T cells, also are negatively affected by lentiviral infection and may be dysfunctional. 
Epithelial disturbance is also observed in HIV infection. 
 
HIV infection also interferes with stromal and epithelial cells of the intestinal mucosa. During 
acute SIV infection massive apoptosis occurs in the gut epithelium152. Pro-inflammatory 
genes are up-regulated, and genes responsible for epithelial regeneration and 
digestive/metabolic functions are down-regulated153. Notably, in chronic infection, a pro-
inflammatory milieu marked by up-regulation of IL-6 and STAT3 persists154, and mucosal IL-
2, IL-4 and TNF-? are increased, leading to increased epithelial permeability155. Intestinal 
inflammation and epithelial apoptosis not only impairs the gastrointestinal barrier, chronic 
inflammation also has negative effects on overall tissue architecture. GALT tissue from HIV-
infected patients shows marked fibrosis, and the amount of collagen deposition is even higher 
than in other lymphatic organs156. In lymph nodes, intense fibrosis correlates with low CD4+ 
T-cell counts and poor T-cell reconstitution under HAART157,158, and the same very likely 
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applies to GALT fibrosis. This observation explains the slow and poor reconstitution of 
GALT lymphocytes under HAART, despite suppression of the local mucosal inflammation 
and permeability changes mediated by successful antiretroviral treatment155. 
In summary, accumulating data indicate that HIV causes a profound and complex disturbance 
of the mucosal immune function. The deleterious effects of HIV are not limited to CD4+ T 
cells. In chronic HIV infection, disturbed GALT function and microbial translocation are 
accompanied by an incessant vicious circle of immune activation and inflammation with 
deleterious consequences on viral replication, T-cell and epithelial cell death, and dysfunction 
of multiple additional cells (Fig. 2). 
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Conclusions 
The GALT is one of the major organs affected by HIV infection. Viral replication and T-cell 
loss are even more pronounced in the intestinal lamina propria than in other lymphoid tissues. 
Furthermore, in chronic HIV infection, a poorly controlled translocation of bacterial products 
(e.g., LPS) occurs and correlates with immune activation markers, which in turn are 
associated with disease progression. Recently, a handful of studies identified the critical role 
of Th17 cells in this process. During pathogenic lentiviral infections, Th17 function in the 
GALT is reduced and invasion of gut bacteria—directly shown so far only with Salmonella—
is increased.  
However, many questions remain. Cause and effect relations in this circle of immune 
dysfunction and bacterial translocation are difficult to pin down. Consequently, one cannot 
predict if reduction of bacterial translocation or immune activation would be a beneficial 
therapeutic approach. Studies with compounds blocking immune activation so far did not 
show positive effects159,160, maybe due to a general immunosuppressive effect of these drugs. 
Despite reduced immune activation, which may prevent further deterioration of immune 
functions, such drugs will also reduce immune responses directed against the virus. The 
optimal therapy should reduce the damaging general activation of immune cells, boost HIV-
specific immune responses, and activate antimicrobial defense at mucosal surfaces to reduce 
translocation of gut microbes.  
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Bacterial translocation from the gut and subsequent immune activation are hallmarks of 
HIV infection and are thought to determine disease progression. Intestinal barrier 
integrity is impaired early in acute retroviral infection, but levels of plasma 
lipopolysaccharide (LPS), a marker of bacterial translocation, increase only later. We 
examined humanized mice infected with HIV to determine if disruption of the intestinal 
barrier alone is responsible for elevated levels of LPS and if bacterial translocation 
increases immune activation. Treating uninfected mice with dextran sodium sulfate 
(DSS) induced bacterial translocation, but did not result in elevated plasma LPS levels. 
DSS-induced translocation provoked LPS elevation only when phagocytic cells were 
depleted with clodronate liposomes (clodrolip). Macrophages of DSS-treated, HIV-
negative mice phagocytosed more LPS ex vivo than those of control mice. In HIV-
infected mice, however, LPS phagocytosis was insufficient to clear the translocated LPS. 
These conditions allowed higher levels of plasma LPS and CD8+ cell activation, which 
were associated with lower CD4+/CD8+ cell ratios and higher viral loads. LPS levels 
reflect both intestinal barrier and LPS clearance. Macrophages are essential in 
controlling systemic bacterial translocation, and this function might be hindered in 
chronic HIV infection. 
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Summary 
HIV infection leads to continuous destruction of the body’s immune defenses. Furthermore, 
disease progression is linked to heightened levels of immune activation. However, the 
underlying activating factors and their relationships to HIV pathogenesis are controversial. In 
patients with chronic HIV infection, bacteria and their products, such as lipopolysaccharide 
(LPS), translocate from the intestinal lumen into the systemic circulation. In the current study, 
we investigated the pathogenic potential of bacterial translocation in HIV-infected humanized 
mice. By modulating the amount of bacterial translocation in the mice, we determined that 
LPS elevation depends on intestinal barrier dysfunction and defective LPS clearance by 
macrophages. HIV-infected mice showed inadequate LPS clearance, leading to a cascade of 
uncontrolled bacterial translocation, T-cell activation, HIV replication, and T-cell loss. Our 
study highlights how important the interplay between different immune cells is for 
maintaining a healthy balance between immune activation with the goal to defend the body 
against microbes and detrimental activation that fuels HIV replication. 
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Introduction 
The clinical course of HIV infection varies considerably among patients, and the variability is 
even greater in simian models. Asian monkeys infected with simian immunodeficiency virus 
(SIV) rapidly progress to AIDS, but African monkeys do not get sick110. In general, a 
pathogenic course of retroviral infection is characterized by high levels of immune 
activation161, and bacterial translocation from the intestinal tract has been implicated as an 
underlying activating mechanism56,120-124. The integrity of the intestinal barrier is impaired 
early in acute retroviral infections162, and a substantial fraction of the intestinal CD4+ T cells 
are lost within days after infection8,112.  
However, bacterial translocation manifests itself only later. Low T-cell numbers in the gut are 
an important characteristic of HIV or SIV pathogenesis111,163, but intestinal CD4+ T-cell 
depletion does not predict the outcome of SIV infection in monkeys118. In SIV-infected 
African monkeys, for example, bacterial translocation is prevented despite low numbers of 
intestinal CD4+ T cells57. Thus, intestinal CD4+ T-cell depletion alone cannot explain 
bacterial translocation and the subsequent rise in plasma lipopolysaccharide (LPS) levels in 
chronic HIV infection56. Preferential depletion of Th17 cells is associated with disruption of 
the intestinal barrier in pathogenic retroviral infections140,142, but overall, the mechanism 
linking bacterial translocation and HIV pathogenesis is not fully understood. 
Seeking evidence for this mechanism, we examined relationships among intestinal barrier 
integrity, microbial translocation, immune activation, and HIV replication in a mouse-model 
of HIV infection. In this model, RAG2-/-?c-/- mice are transplanted with human cord-blood 
hematopoietic stem cells. A human lymphoid system develops67, and the “humanized” mice 
can be infected with HIV68,79,82. The humanized mice combine the advantages of studying 
HIV in human cells and in a small-animal model that facilitates experimental manipulations. 
Furthermore, these mice have low intestinal lymphocyte numbers164. In HIV infection, low 
numbers result mostly from virus-mediated depletion. In the humanized mice, however, they 
result from a low local level of engraftment by human cells. Thus, in the humanized mice, low 
numbers of intestinal T cells are uncoupled from the effects of viral replication. Moreover, the 
intestinal barrier can be disrupted by adding dextran sodium sulfate (DSS) to the drinking 
water of mice87. DSS treatment leads to apoptosis165 and reduced proliferation of intestinal 
epithelial cells166, mimicking the enterocyte apoptosis seen in SIV infection152.  
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In the current study, we dissected the effects of bacterial translocation alone or in the context 
of HIV infection by combining DSS and HIV in humanized mice. We defined the 
consequences of HIV infection and bacterial translocation on plasma LPS levels, LPS 
clearance by macrophages, immune activation, and T-cell loss. 
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Results 
DSS treatment or HIV infection induce a similar amount of bacterial 
translocation 
In a DSS dose-response experiment, we established a treatment protocol that increases 
bacterial translocation without inducing colitis (Fig. S1). Briefly, we quantified bacterial 
translocation in groups of HIV-uninfected and -infected mice with mock or DSS treatment 
(i.e., HIV-/DSS-, HIV-/DSS+, HIV+/DSS-, or HIV+/DSS+ mice). We infected humanized 
mice with the CCR5-tropic HIV strain YU-2 and verified the infection by RT-PCR of plasma 
HIV RNA 4–6 weeks after inoculation. Thereafter, infected and uninfected control mice were 
treated with 0 or 0.75% DSS for 2 weeks. We cultured organ suspensions of mesenteric 
lymph nodes (MLN) and spleens, quantified bacterial colonies (Fig. 1A), and calculated a 
translocation index, based on quantity, diversity, and location of recovered bacteria (Fig. 1B). 
HIV-/DSS- control mice showed some baseline translocation with roughly a third of the 
animals containing bacteria in the MLN suspensions. Only few animals showed systemic 
dissemination to the spleen. DSS treatment increased bacterial translocation; in HIV-/DSS+ 
mice percentages of cultures containing bacteria doubled, and particularly in the spleen 
bacterial loads were higher.  
 
 
Supplementary Figure 1: DSS induced bacterial translocation in humanized mice. 16 uninfected mice were 
treated with different doses of DSS in the drinking water for 2 weeks. (A) Systemic bacterial load was assessed 
by semi-quantitative (+ black bar, ++ white bar, +++) microbiological culture of organ suspension from 
mesenteric lymph nodes, spleen and liver. (B) Mouse weight as an indicator for diarrhea and colitis was 
measured daily (mean). This experiment was done once. 
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 Figure 1. Gastrointestinal barrier dysfunction did not completely explain HIV-associated plasma LPS 
elevation in humanized mice. 4 to 6 weeks after HIV or mock infection, humanized mice received DSS 0.75% 
or normal drinking water for 2 weeks. (A) In cultures of mesenteric organ suspensions, bacterial colony forming 
units from MLN (white bar) and spleens (black bar, mean, SD) were quantified; percentages of positive organs 
in the different groups are indicated at the bottom of the respective bars (n=50, pooled data from two 
independent experiments). (B) The mice showed a trend towards higher levels of bacterial translocation 
(assessed by an index that includes number, species, and location of bacteria detected, P=0.1, 0.08 and 0.13, 
respectively) after HIV infection or DSS treatment. (C) DSS+/HIV- mice (black square) had plasma LPS levels 
similar to those of control mice (black circle). Only HIV+ mice without (white circle, *, P=0.015) or with DSS 
treatment (white square, **, P=0.005) showed significant increases of plasma LPS (n=59, pooled data from two 
independent experiments). (D and E) Both groups of HIV+ mice showed a trend towards higher plasma sC14 
(P=0.06 for HIV+/DSS- and P=0.1 for HIV+/DSS+ mice) and had significantly higher LBP values (***, 
P=0.0006 for HIV+/DSS- and **, P=0.008 for HIV+/DSS+ mice). 
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Organ cultures yielded mainly Lactobacilli, Staphylococcus xylosus, a typical mouse 
commensal, and Enterococci, whereas stool cultures yielded a multitude of aerobic and 
anaerobic bacteria. Only some bacterial species translocated to the organs in sufficient 
numbers to be cultured. HIV+ mice had similar microbiology results to HIV-/DSS+ mice. 
Overall, the range and amount of translocation were comparable between HIV-/DSS+, 
HIV+/DSS-, and HIV+/DSS+ mice. HIV infection alone seemed to facilitate bacterial 
invasion from the gut, and DSS treatment did not further increase the bacterial translocation in 
HIV+ humanized mice. 
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Bacterial translocation does not always induce LPS elevation 
In humans bacterial translocation is quantified by measuring surrogate markers, such as 
plasma LPS, soluble CD14 (sCD14), or LPS binding protein (LBP). We compared these 
markers to the direct measurement of intestinal barrier function in humanized mice. 
Plasma LPS measurements showed a contrasting picture to microbiology results. Only HIV+ 
mice exhibited elevated levels of LPS in the systemic circulation. HIV-/DSS+ mice, which 
had increased intestinal permeability according to the organ culture results, controlled plasma 
LPS levels (Fig. 1C). In accordance with the elevated LPS levels, HIV+ mice also exhibited 
higher plasma sCD14 and LBP levels (Fig. 1D and E). We did not measure endotoxin core 
antibodies (EndoCAb) since humanized RAG2-/-?c-/- mice in general have very poor antibody 
responses, serum immunoglobulin concentrations are several log lower than in humans 67, and 
mostly IgM is produced with IgG appearing only several months after humanization 82. 
The HIV+ mice might have had a greater influx of smaller bacterial products and as a 
consequence higher plasma LPS levels. To eliminate this possibility, we measured the 
integrity of the intestinal barrier by gavaging mice with fluorescein isothiocyanate (FITC)-
dextran with a molecular weight similar to that of LPS (Fig. S2B). Furthermore, we included 
wild-type and non-humanized mice to determine the consequences of irradiation and 
transplantation. After 4 hours, FITC-dextran was detected at similar concentrations in the 
plasma of HIV-/DSS- control mice, wild-type BALB/c, and non-humanized RAG2-/-?c-/- mice. 
Thus, independent of humanization, RAG2-/-?c-/- and wild-type mice had equal intestinal 
permeabilities, and the absence of intestinal lymphocytes had little effect on permeability in 
this model. In DSS-treated or HIV-infected mice there was a trend towards higher FITC-
dextran values. In histological sections of the intestines, we found no evidence for 
exacerbated damage in HIV+ mice, and DSS-treated mice showed moderate changes (Fig. 
S2A). 
Defects in intestinal barrier integrity influenced translocation, but alone they were not 
sufficient to induce LPS elevation. In HIV-infected mice, some additional factors contributed 
to higher plasma LPS levels. 
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Supplementary Figure 2: Histological and functional measurement of the intestinal integrity. (A) Formalin 
fixed, haematoxylin and eosin stained tissue sections of HIV infected and/or DSS treated mice showed moderate 
changes of the intestinal mucosa. DSS treatment induced villus blunting, a modest vessel dilation (*) and 
discreet goblet cell hyperplasia (>). (B) Humanized mice (n=32, pooled data from two independent experiments) 
were infected with HIV (white symbols) or mock treated (black symbols) and 4 weeks later received 0 (circles) 
or 0.75% (squares) w/v DSS. After two weeks, in vivo permeability was measured by FITC-dextran (molecular 
weight 10,000, Sigma) translocation. Mice were gavaged with FITC-dextran 20 mg/20 g body weight in 200µl 
PBS and four hours later FITC fluorescence in the plasma was measured. Wild-type (WT, block arrow up) and 
non-humanized RAG2-/-c?-/- (RAG2, block arrow down) mice were included as a control. HIV-/DSS+ mice had 
higher FITC-dextran plasma values (*, P=0.012) than WT, non-humanized and HIV-/DSS- control mice. Both 
HIV+ groups showed only a trend towards higher FITC-dextran translocation. 
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Bacterial translocation can be compensated for by increased macrophage 
phagocytosis 
We hypothesized that plasma LPS levels are a marker for bacterial translocation and for the 
clearance of bacterial products from the systemic circulation. One of the main LPS clearance 
mechanisms is phagocytosis by liver macrophages167,168. We tested the influence of LPS 
clearance on plasma LPS levels by depleting macrophages in the humanized mice. Clodronate 
liposomes induce apoptosis of phagocytic cells, thus humanized mice injected with clodronate 
liposomes exhibited a strong reduction of macrophage numbers (Fig. 2A). When we 
simultaneously treated the mice with 0.75% DSS for 1 week, plasma LPS levels increased 
(Fig. 2B). Disturbing the intestinal barrier or reducing the number of macrophages alone 
caused no change in plasma LPS.  
To assess macrophage function during HIV infection, we isolated liver macrophages from all 
four groups of mice (i.e., HIV-/DSS-, HIV-/DSS+, HIV+/DSS-, and HIV+/DSS+ mice) and 
incubated the cells ex vivo with FITC-LPS (Fig. 2C). All macrophages took up some LPS, but 
cells isolated from HIV-/DSS+ mice up-regulated their phagocytic capacity significantly 
compared to cells from control animals. Cells from HIV+ mice showed a slight, statistically 
insignificant increase of LPS phagocytosis (Fig. 2D). Further evidence of altered macrophage 
function in HIV+ mice was an increase of pro-inflammatory cytokines, such as IL-12 and 
TNF-? in the plasma (FigS3). Macrophage numbers in liver and intestines were similar in all 
groups (data not shown). The results imply that bacterial translocation and LPS influx can be 
compensated for by increased LPS phagocytosis and that this function was disturbed in HIV-
infected mice.  
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 Figure 2: The combination of a bacterial translocation and disturbed LPS clearance induces plasma LPS 
elevation. (A) Humanized mice were injected intraperitoneally with clodrolip (1 mg/20 g body weight) to 
deplete phagocytic CD11b intermediate cells (spleens of representative mock PBS or clodrolip treated mice 48 h 
after injection). (B) After 1 week of DSS 0.75% (square, block arrow down) treatment and a second injection of 
clodrolip (0.5 mg/20 g body weight) (block arrow up, block arrow down), plasma LPS was only increased in 
mice that received both treatments (*, P=0.006, n=37, pooled data from two independent experiments). (C) Liver 
macrophages, isolated from HIV- or HIV+ mice that received either normal drinking water or 0.75% DSS for 2 
weeks, were incubated ex vivo with FITC-LPS at 37°C or 4°C (shaded or open histogram), and mean 
fluorescence intensity of phagocytic cells (values upper right corner) was measured. (D) Values were normalized 
to the mean FITC-LPS signal of cells from HIV-/DSS- mice (black circle). DSS-induced bacterial translocation 
increased FITC-LPS phagocytosis (black square, ***, P<0.0001), but HIV infection abrogated this effect (white 
circle, P=0.2), independent of DSS treatment (white square, P=0.19) (n=59, pooled data from two independent 
experiments). 
66 
 Figure S3. Macrophage derived pro-inflammatory cytokines in HIV+ mice. We measured plasma cytokine 
levels by cytometric bead assay (A.Urwyler, Cytolab) in HIV-/DSS- (black circle), HIV-/DSS+ (black square), 
HIV+/DSS- (white circle), and HIV+/DSS+ animals (white square). (A and B) Both human (left) and murine 
(right panel) cytokines were assessed. HIV+ mice showed a trend towards higher human (P=0.084 and 0.096) 
and murine TNF-alpha levels (*, P=0.045 and P=0.11 for DSS- and DSS+ mice). (C and D) Human IL-12p40 
was below detection limit in many of the animals, while murine IL-12p40 was significantly elevated in HIV+ 
mice (***, P=0.0006, and **, 0.004 for DSS- and DSS+ mice). IL-1beta was undetectable in all mice and IL-6 
values showed no significant differences (data not shown). 
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Bacterial translocation activates T cells  
Since bacterial translocation has been implicated in immune activation during chronic HIV 
infection, we examined the effects of bacterial translocation alone or in the context of HIV 
infection on the expression of cell-surface markers of T-cell activation. We determined T-cell 
activation levels in the spleens of humanized mice by measuring percentages of CD38 HLA-
DR double positive cells in human CD4+ or CD8+ cells (Fig. 3A). CD4+ cells from HIV-
/DSS+ animals showed a slight increase of activation, but activation of CD8+ cells was more 
apparent (Fig. 3B). Both groups of HIV-infected mice had even higher CD8+ cell activation 
levels, with no difference between DSS- and DSS+ groups. There was a trend towards slightly 
higher CD4+ cell activation in HIV+ mice. 
Thus, bacterial translocation, even if no detectable plasma LPS elevation occurred, activated 
CD4+ and CD8+ cells in HIV- mice. In HIV+ mice, where levels of plasma LPS were 
increased, CD8+ cell activation was even stronger. 
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 Figure 3: HIV infected humanized mice have high levels of CD8+ T cell activation. Control (black symbols) 
or HIV-infected mice (white symbols) received normal drinking water (circles) or 0.75% DSS (squares) for 2 
weeks. (A) Activation levels in the spleen were determined by flow cytometry of human HLA-DR and CD38 
staining of CD45+CD8+ (one representative animal per group) and CD45+CD4+ splenocytes. (B) DSS 
treatment alone slightly increased activation levels of CD4+ (*, P=0.004) and CD8+ cells (*, P=0.007), over 
those in uninfected, untreated control mice. HIV infection drastically increased CD8+ cell activation in animals 
that received normal (***, P<0.0001) or DSS (***, P<0.0001) water (n=50, pooled data from two independent 
experiments). 
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T-cell activation promotes viral replication and CD4+ T-cell loss 
In HIV- mice, levels of CD4+ and CD8+ cell activation were tightly correlated (Fig. 4A). If 
that relationship of CD4+ and CD8+ cell activation was the same in HIV+ mice, then CD4+ 
cell activation levels should have been even higher in HIV+ mice than in HIV-/DSS+ mice. 
The correlation between activation levels of CD4+ and CD8+ cells in HIV+ mice, however, 
was partially lost (Fig. 4B), and the HIV+ mice had a relative deficit of activated CD4+ cells. 
In humanized mice, absolute CD4+ T-cell numbers differ, because the efficiency of human 
engraftment is variable. However, CD4+/CD8+ cell ratios are independent of engraftment and 
are, thus, reasonably reliable estimates of CD4+ cell depletion.  
The ratios were similar for all four groups (Fig. S4A). Individual variations of CD4+/CD8+ 
cell ratios between mice were probably too large to detect small changes between groups in 
the relatively short time of the experiment. Furthermore, no difference in HIV replication was 
observed between HIV+/DSS- and HIV+/DSS+ mice (Fig. S4B). Nevertheless, in HIV+ 
mice, percentages of activated CD8+ cells correlated with lower CD4+/CD8+ cell ratios (Fig. 
4C). Hence, HIV+ mice with high levels of CD8+ cell activation lost more CD4+ cells. No 
correlation between CD4+/CD8+ cell ratios and CD8+ cell activation was seen in HIV- mice 
(data not shown, P=0.423, r=0.190). In the absence of HIV infection, no loss of CD4+ cells 
occurred, indicating that HIV causes the preferential loss of activated CD4+ cells. Indeed, 
higher CD8+ cell activation levels—this time calculated in relation to total splenocytes to take 
engraftment level also into account—correlated with higher viral loads (Fig. 4D). In the HIV+ 
humanized mice, activation of CD4+ cells seemed to be masked by HIV infection and rapid 
loss of these cells, maybe even before full expression of activation markers. 
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Figure 4: Activation of CD8+ cells is associated with lower CD4+/CD8+ ratios and higher viral loads in 
HIV infected mice. Human CD8+ splenocyte activation levels defined by HLA-DR+ and CD38+ co-staining 
from HIV-/DSS- (black circle), HIV-/DSS+ (black square), HIV+/DSS- (white circle), and HIV+/DSS+ animals 
(white square) were correlated with CD4+ cell-activation levels, CD4+/CD8+ cell ratio, and viral load. (A) In 
uninfected mice, activation levels of CD8+ and CD4+ cells were tightly correlated (n=23, pooled data from two 
independent experiments). (B) But in HIV+ mice, this relationship was not as clear (n=27, pooled data from two 
independent experiments). (C) In HIV+ mice, higher percentages of activated CD8+ cells correlated with lower 
CD4+/CD8+ cell ratios. (D) When activation levels were adjusted for overall engraftment by calculating 
percentages of HLA-DR+CD38+CD8+ cells of total cells, including murine cells, CD8+ cell activation 
correlated also with higher viral loads. 
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Supplementary Figure 4: Diversity of CD4/CD8 ratios and viral loads in humanized mice. Humanized mice 
were infected with HIV (white symbols) or mock treated (black symbols) and 4 weeks later received 0 (circles) 
or 0.75% (squares) w/v DSS. (A) After 2 weeks, spleens were removed and splenocytes were analyzed for 
human CD4+ and CD8+ T-cell ratios by flow cytometry (n=50, pooled data from two independent experiments, 
no significant differences). (B) Plasma viral load was measured (n=27, pooled data from two independent 
experiments), 48 h before the beginning of DSS treatment (baseline, no significant difference), and at the end of 
the experiment (after DSS, no significant difference). 
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Discussion 
Dysfunction of the intestinal barrier has severe consequences for the whole organism. It leads 
to translocation of bacteria from the gut and mediates inflammation. In chronic HIV infection, 
for instance, elevated levels of circulating bacterial products are associated with T-cell 
activation and disease progression56. We established a humanized mouse model of intestinal 
barrier dysfunction to determine the systemic effects of bacterial translocation. In our model, 
permeability corresponded well with translocation. But plasma LPS levels, the classical 
marker of bacterial translocation, depended only partially on barrier dysfunction. 
Macrophages compensated for the increased bacterial translocation by up-regulating their 
phagocytic capacity and thereby kept plasma LPS levels in a normal range. In HIV-infected 
mice, however, LPS clearance was inadequate leading to increased plasma LPS levels, high 
T-cell activation, and vigorous HIV replication. 
A multilayered barrier protects the body from invading intestinal bacteria. The first line of 
defense is a tight, mucus-coated sheath of intestinal epithelial cells. Moreover, leukocytes in 
the underlying lamina propria contribute to the protection against bacteria. The humanized 
mice we used have low intestinal lymphocytes numbers164. Therefore, changes of the 
epithelial integrity probably have a relatively big impact on translocation in humanized mice, 
even without obvious histopathological changes. While there was no obvious difference in 
FITC-dextran translocation between humanized and wild-type mice, intestinal permeability 
tended to increase after HIV infection or low dose DSS treatment (Fig. S2B). Notably, HIV+ 
mice had high plasma TNF-? levels (Fig. S3). TNF-? disrupts tight junctions and induces 
apoptosis of intestinal epithelial cells169, thereby mediating barrier dysfunction. Baseline 
translocation in HIV-/DSS- mice was quite high with one third of the MLN cultures 
containing bacteria (Fig. 1A and B). HIV+ or DSS+ mice more frequently had bacteria 
translocating to MLN and spleen—in accordance with the increased FITC-dextran 
permeability. From our data, it is not possible to infer the exact role disturbance of epithelial 
permeability and intestinal lymphocyte depletion plays in human HIV infection. But in 
general, the amount of bacterial translocation depends on barrier integrity. 
Surprisingly, plasma LPS levels showed a different pattern (Fig. 1C). They did not depend 
strictly on permeability and translocation. In our experiments, HIV+ mice had elevated 
plasma LPS levels. HIV-/DSS+ mice controlled the increased influx of bacteria from the gut 
by raising their ability to clear LPS. LPS elevation only occurred in animals that had 
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disturbance of the intestinal barrier and at the same time LPS clearance defects, either because 
of macrophage depletion or HIV infection (Fig. 2). Thus, macrophage phagocytosis seems to 
be critical in protecting against systemic translocation and failed clearance leads to systemic 
elevation of bacterial products. This hypothesis is supported by studies of inflammatory bowel 
disease. Plasma LPS levels are elevated in active inflammatory bowel disease, when the 
intestinal barrier is disrupted123. Furthermore, patients with Crohn’s disease clear 
subcutaneously injected bacteria very slowly, their macrophages secrete few pro-
inflammatory cytokines in response to bacteria or TLR ligands, and the transcription profiles 
of these macrophages show defects in vesicle trafficking and cytoskeletal organization 170. 
This indicates that defects similar to the dysfunctional macrophage phagocytosis seen in our 
model might be important in inflammatory bowel diseases. 
The mechanism leading to macrophage dysfunction in HIV+ mice is not clear. It is tempting 
to postulate induction of an “endotoxin-tolerant” macrophage phenotype in HIV-/DSS+ mice, 
and loss of tolerance induction in HIV+ mice. Endotoxin tolerance is characterized by 
programming of macrophages towards phagocytosis instead of production of pro-
inflammatory cytokines upon LPS re-exposure171. Indeed, plasma IL-12 and TNF-? levels 
were normal in HIV-/DSS+ mice despite increased bacterial translocation. In contrast, HIV+ 
mice had high levels of pro-inflammatory cytokines (Fig. S3). At the moment, the factors 
inhibiting tolerance induction are unknown. Duration of translocation might play a role: HIV-
/DSS+ mice had barrier dysfunction for the relatively short period of two weeks. Control of 
longer lasting translocation might not be as easy. Otherwise, the pro-inflammatory state 
generated by HIV infection might influence macrophage function. Macrophages integrate a 
broad range of environmental information. Some cytokines172 and bacterial products173,174 
sensitize cells to LPS stimulation. Furthermore, viral products and/or cytokines produced due 
to virus infection interfere with endotoxin tolerance induction in chronically HCV-175 or HIV-
176 infected patients. Instead monocytes from these patients produce more TNF-? upon LPS 
re-stimulation. 
So far, it is unknown if LPS clearance dysfunction also exists in HIV-positive humans, 
although some evidence supports the existence of macrophage defects in chronic HIV 
infection. Plasma LPS levels in acutely HIV-infected patients are not elevated56, despite early 
depletion of gut lymphocytes. During treatment interruption, LPS levels rise only after a few 
weeks of viral replication124. Early after antiretroviral therapy is stopped, falling EndoCAb 
levels indicate functional LPS clearance. Thereafter, elevation of LPS levels suggests the 
74 
onset of clearance defects. In fact, HIV inhibits macrophage maturation177 and 
phagocytosis178,179. Monocytes from HIV-infected individuals show impaired Mycobacterium 
phagocytosis180; Saccharomyces up-take is also decreased, and LPS-mediated enhancement of 
phagocytosis is less than the enhancement in monocytes from healthy donors181. Moreover, 
monocytes from HIV-infected patients show an attenuated pro-inflammatory cytokine 
response to LPS stimulation ex vivo56,182, maybe due to in vivo pre-stimulation. Serum IL-12 
and TNF-? levels, which reflect in vivo cytokine production, are higher183-186- similar to the 
increased cytokine levels we observed in HIV+ mice. Overall, our findings in HIV-infected 
humanized mice resemble the results from HIV-infected humans. 
Certainly, not all aspects of human HIV infection can be modeled accurately in humanized 
mice. For example, direct HIV infection of macrophages is rare in the mice. Engraftment of 
human monocytes was low; less than 2% of all monocytes were of human origin (data not 
shown). Most macrophages are of murine origin and therefore resistant to HIV infection. In 
humans, macrophage permissiveness to HIV infection varies from tissue to tissue. For 
example, intestinal macrophages are quite resistant to infection, but vaginal macrophages are 
readily infected187. However, productive infection of macrophages is, in general, infrequent in 
vivo70, except for late stages of disease when opportunistic infections occur188. To definitely 
determine the importance of direct viral infection of macrophages, other models with bigger 
populations of human myeloid cells would be useful. 
Lymphoid engraftment, however, is quite good in humanized mice. This allowed the 
investigation of T-cell activation in DSS-treated or HIV-infected mice. Bacterial translocation 
induced CD4+ and CD8+ cell activation (Fig. 4). Other activating factors (i.e., stimulation of 
TLR7/8 by HIV RNA189-191) might also have played a role. However, in HIV-/DSS+ mice, 
such other activating factors were not present, and bacterial translocation alone activated T 
cells. Since plasma LPS levels were not elevated in these mice, immune activation might have 
been mediated by other bacterial components, such as peptioglycan, flagellin, or bacterial 
DNA. Moreover, LPS flux—input from the gut and subsequent clearance—was greater in 
these mice. A greater LPS flux might activate the immune system. At least, it induced and 
sustained stimulation of macrophage phagocytosis. Uncontrolled bacterial translocation, as 
seen in HIV+ mice, might reasonably caused higher levels of lymphocyte activation. Not 
surprisingly, DSS treatment had no effect on T-cell activation in HIV+ mice. The bacterial 
translocation indices and LPS phagocytosis capacities were almost identical in HIV+/DSS- 
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and HIV+/DSS+ groups, leading to similar LPS, LBP and sC14 levels and, therefore, to 
similar activation levels. 
Our results might explain why levels of CD8+ T-cell activation are especially good markers 
of disease outcome72, even though CD8+ T cells are not direct viral targets. In HIV-
uninfected mice CD8+ and CD4+ cell activation levels were tightly correlated. CD8+ T-cell 
activation levels seem to predict the amount of activated and HIV-permissive CD4+ T cells. 
These cells have a very short lifespan; the half-life of an infected CD4+ T cell is estimated at 
1.6 days192. Additionally, measurements of lymphocyte telomere lengths indicate that, in 
HIV-infected individuals, only CD8+ T-cell turnover is increased, while telomeres in CD4+ T 
cells show no excessive turnover193. CD4+ T cells might be lost due to HIV infection before 
cell division is accomplished. This could also explain the relative deficit of activated CD4+ 
cells we observed in HIV+ animals. HIV preferably infects activated CD4+ cells144. Indeed, 
those mice with the highest percentages of activated CD8+ cells had the lowest CD4+/CD8+ 
cell ratios and the highest HIV plasma loads. 
In conclusion, we identified a critical role of macrophages in protection from systemic 
bacterial translocation. In humanized mice, failure of LPS clearance was associated with high 
levels of T-cell activation and HIV replication. Macrophage dysfunction might be an 
underestimated mechanism in HIV-induced immunodeficiency and certainly warrants further 
investigation. 
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Material and Methods 
Ethics Statement 
All experiments were approved by ethical committees of the University Zurich and the 
Federal Veterinary Department and were conducted according to local guidelines (TschV, 
Zurich) and the Swiss animal protection law (TschG). Cord blood was collected with written 
consent of the parents. 
Generation and HIV infection of humanized mice 
Mice were reconstituted and infected as described68. Briefly, newborn RAG2-/-c?-/- mice were 
irradiated with 2x2 Gy. CD34+ cells were isolated from human cord blood with 
immunomagnetic beads (Miltenyi Biotec), and 2.75 ± 0.5 x 105 cells were transplanted into 
each mouse. After 10 to 16 weeks, the degree of blood engraftment was determined by flow 
cytometry of peripheral blood mononuclear cells stained for the panhuman marker CD45 in 
all mice (mean human cells/live cells 5.6 ± 5.4% SD). Mice were infected intraperitoneally 
with HIV YU-2, 2 x 105 of the tissue-culture infectious dose50 per mouse. Plasma viral loads 
were measured by RT-PCR (Amplicor, Roche) 4–6 weeks after inoculation and at the end of 
each experiment. The detection limit was 1,600 HIV RNA copies/ml. Activation levels of T 
cells were measured by flow cytometry of splenocytes stained for human CD45, CD4, CD8, 
HLA-DR, CD38, and appropriate isotype controls (all from BD Biosciences). In all 
experiments, mouse litters and cord blood donors were evenly distributed to all experimental 
groups.  
Induction and measurement of bacterial translocation 
Bacterial translocation was induced by adding 0.75% (w/v) DSS (molecular weight 40,000, 
MP Biomedicals) to the drinking water for 2 weeks. Spleen and MLN were removed 
aseptically, mashed with a pestle in PBS, and plated on sheep blood and MacConkey agar 
plates. Plates were only incubated aerobically, since in a pilot experiment, no anaerobic 
bacteria could be detected in organ cultures. As a control, diluted stool samples were cultured 
both in aerobic and anaerobic conditions. A descriptive bacterial translocation index was 
calculated from organ culture results (no bacterial growth = 0 points, 10 to 99 cfu/organ = 1 
point, 100 to 999 cfu/organ = 2 points, >1000 cfu/organ = 3 points, for all organs points were 
multiplied by the number of bacterial species detected. For spleen cultures, points were 
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doubled, and finally, all points from one mouse were added up). LPS was quantified by 
endpoint chromogenic limulus amoebocyte lysate assay (Lonza). Plasma samples were diluted 
1:10 with endotoxin free water, incubated at 85°C for 12 min, and assayed according to the 
manufacturer’s instructions. Standard endotoxin (Lonza) was diluted to cover plasma LPS 
values within a range of 0.5 to 20 EU/ml. Plasma mouse sCD14 and LBP were measured by 
ELISA (both from CellSciences), according to the manufacturer’s instructions. For sCD14 
measurement, samples were diluted 1:150, and for LBP measurement, 1:800. 
Ex vivo LPS phagocytosis 
Liver mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation. To 
further purify macrophages, cells were incubated for 3 h in RPMI, 10% FCS, 
penicillin/streptomycin, and L-glutamine at 37°C, 5% CO2, and then washed two times with 
room temperature PBS to remove non-adherent cells. This procedure yielded over 90% 
murine CD11b+ cells. Cells were then incubated with 0.1 mg/ml FITC-LPS (Sigma) in RPMI, 
10% FCS, penicillin/streptomycin, and L-glutamine at 37°C, 5% CO2 for 1 h. As a control, 
cells were also incubated with FITC-LPS at 4°C. Cells were then washed two times with cold 
PBS, detached with trypsin, washed once again, and analyzed by flow cytometry. FITC-LPS 
mean fluorescent intensity was normalized to the fluorescence of samples from HIV-/DSS- 
mice. 
Macrophage depletion 
Mice were injected intraperitoneally with clodrolip (1 mg/20 g body weight) or with PBS194. 
After 48 h, depletion was verified in four mice by staining of spleen and liver cells for 
CD11b. To maintain depletion, mice were treated a second time with clodrolip 0.5 mg/20 g 
body weight or with PBS intraperitoneally 4 days after the first injection. Concurrently, half 
of the mice received DSS 0.75% (w/v) in their drinking water. After 1 week, the mice were 
sacrificed, and their plasma LPS levels were measured. 
Statistical analysis 
GraphPad Prism 5.02 was used for statistical analysis. Data were analyzed by parametric one-
way analysis of variance, followed by Bonferroni post-test. All p-values shown are adjusted 
for multiple comparisons. In the figures, p-values are presented for comparisons between 
treatment groups and controls and are denoted by asterisks. Values for HIV/DSS experiments 
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for plasma LPS, viral load, FITC-dextran fluorescence, and percentages of activated CD8+ 
cells (of total cells) were log transformed before analysis to reduce right-skewing of the data. 
For all correlations, Pearson’s correlation coefficient was calculated. In all figures, points 
represent values of individual mice, and lines depict mean values. 
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5.1 Mouse models of rectal HIV transmission 
Intestinal engraftment and transmission rates in different models 
Millions of people worldwide are infected with HIV. Despite improved treatment strategies 
and efforts in prevention, no end of the pandemic is in view195. A major goal is to prevent new 
HIV infections74. For a rationale design of prevention methods, we need a detailed knowledge 
of HIV transmission and the early steps in HIV infection196. However, the field of HIV 
research has long been hampered by the lack of a small animal model that mirrors HIV 
infection in humans62 and permits to study questions such as vaginal or rectal transmission61. 
Recent advances in the generation of humanized mice now allow experiments with HIV in 
vivo. Injection of human cord blood CD34+ cells into newborn RAG2-/-yc-/- mice leads to 
development of human T, B, and dendritic cells, and successive formation of primary and 
secondary lymphoid organs67, and in these humanized mice experiments with HIV can be 
performed in vivo68. In the current work, we evaluated this model for studying rectal HIV 
transmission. We found that in the humanized intestinal engraftment was disproportionately 
low compared to engraftment in other lymphoid organs. Thus, rectal HIV transmission rarely 
was successful, even in conditions associated with a high transmission risk. Neither local 
treatment with the pro-inflammatory cytokine IL-1? nor colitis induction with DSS increased 
rectal HIV transmission rates (Chapter 2). Additionally, we explored the potential of seminal 
components, known to enhance HIV infection rates in vitro90, to facilitate rectal HIV 
transmission in our humanized mouse model, but no transmission enhancing effect was 
detectable in vivo (data not shown). Therefore, the value of humanized RAG2-/-yc-/- mice to 
investigate rectal HIV transmission is limited. 
Currently, mice transplanted with human fetal organs, so called BLT mice, are the only mice 
allowing reliable HIV transmission via the rectal route66. Furthermore, they are useful to study 
new prevention strategies197. BLT mice have good intestinal engraftment with human T, B, 
and myeloid cells. Furthermore, the majority of human T-cells in the gut of BLT mice show a 
memory phenotype similar to the one observed in lymphocytes isolated form the human 
intestinal mucosa66. Thus, the GALT of BLT mice resembles the human GALT in many 
aspects. At the moment, the BLT mouse model seems superior to humanized RAG2-/-yc-/- 
mice for studying rectal HIV transmission. 
While co-transplantation of fetal organs and hematopoietic stem cells facilitates and enhances 
engraftment of human cells and might thereby induce repopulation of the GALT, it is rather 
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laborious. BLT mice are generated by first surgically implanting pieces of human fetal liver 
and thymus, and then, after a healing period, the mice are sublethally irradiated and 
transplanted with relatively big number of corresponding stem cells. Consequently, ethical 
and practical reasons prohibit the large-scale use of BLT mice.  
 
Future directions 
Modified humanized mouse models might provide valuable alternatives to BLT mice for 
studying mucosal HIV transmission. Human cord blood derived hematopoietic stem cells are 
widely available and straight forward to isolate, and therefore are the obvious choice as 
transplant source. As transplant recipients a wide range of different mouse strains exist. Other 
immunodeficient mice despite RAG2-/-yc-/- mice might favour human intestinal engraftment. 
NOD/SCID yc-/- (NOG) mice, for instance, have a higher overall, and in particular T-cell 
engraftment than RAG2-/-yc-/- mice198. In preliminary experiments, humanized NOG mice 
seemed to have some human GALT engraftment, although skewed towards the B-cell lineage 
(data not shown). Moreover, the transgenic expression of human factors, such as human MHC 
or human cytokines, might further improve level and range of human immune system 
development in humanized mice. 
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5.2 Bacterial translocation as a cause of HIV pathogenesis 
Mechanistic model 
Chronic immune activation is a distinct feature of HIV infection199. It is one of the best 
prognostic markers for disease progression200, it is associated with impaired immune 
reconstitution in patients on antiretroviral therapy201, and it distinguishes pathogenic from 
non-pathogenic simian immunodeficiency virus (SIV) infection in monkeys59,202. It is 
characterized by an increase in T-cell turnover203, in B-cell dysfuntion204, in frequencies of T-
cells with an activated phenotype205, and in serum levels of pro-inflammatory cytokines206. 
The immune system is put under a constant strain leading to dysregulation and exhaustion of 
immune functions, and finally immunodeficiency207. However, the underlying causes of 
immune activation in chronic HIV infection are poorly defined (reviewed in Chapter 3). 
A potential mechanism is immune activation by circulation of microbial products from the 
gut. Previous studies showed that circulating lipopolysaccharide (LPS), a marker of microbial 
translocation from the gastrointestinal tract, is increased in chronically HIV infected 
individuals and correlates with immune activation levels56. With our unique model of DSS 
treated and/or HIV infected humanized mice, we established an in vivo model of bacterial 
translocation and HIV pathogenesis (Chapter 4). Using this model we identified a new facet 
of HIV induced immunodeficiency, namely inappropriate LPS phagocytosis by macrophages. 
This defect initiates a cascade of uncontrolled bacterial translocation, LPS elevation, T-cell 
activation, and HIV replication (Figure 1). These results propose new ways of thinking about 
the role of bacterial translocation in chronic HIV infection; they emphasize the importance of 
macrophages in controlling the systemic load of bacterial products. Restoring appropriate 
clearance of translocated bacteria might be beneficial in preventing some of the negative 
effects of chronic HIV infection. 
 
intestinal 
lumen
barrier 
dysfunction
bacterial translocation plasma LPS LPS clearance           
macrophage 
dysfunction
T-cell activation HIV replication,
T-cell loss
Figure 1. Uncontrolled 
bacterial translocation fuels 
HIV pathogenesis. HIV 
infection leads to an increased 
intestinal permeability and 
bacterial translocation from the 
gut. Additionally, macrophages 
are not able to clear the 
incoming LPS, leading to a 
vicious circle of increased T-
cell activation and viral 
replication. 
 
Future directions 
Validation of our results with samples from SIV infected monkeys and HIV infected humans 
is a priority. Some evidence suggests the presence of similar macrophage defects in these 
situations (discussed in Chapter 4), but data are incomplete. General phagocytosis defects 
have been documented, but LPS phagocytosis has not been studied so far. Optimally, primary 
liver macrophages should be used for such studies. To get such samples from HIV infected 
humans is however quite difficult. Therefore, mouse models with improved human myeloid 
engraftment are a valid alternative as a source of HIV-infected tissue macrophages. In our 
current RAG2-/-yc-/- mouse model, most myeloid cells are of murine origin, and thus, HIV 
resistant. Therefore, we assume that the macrophage dysfunction we observed in the current 
study is mainly an indirect consequence of HIV infection. The same indirect effect of HIV on 
macrophages might be important in humans. Productive HIV infection of macrophages in 
humans is rare70. 
In a next step, elucidation of the factors regulating macrophage function is essential. Viral 
products might directly affect macrophage phenotype, this could include TLR7 triggering by 
HIV ssRNA68 or Tat-mediated changes208. Indirect effects might include phagocytosis of 
infected, apoptotic cells or cytokines produced by infected cells that activate macrophages. 
Furthermore, translocated, bacterial PAMPs probably will determine functional properties of 
the macrophages. In vitro experiments with myeloid cell lines or monocyte derived 
macrophages will be helpful in deciphering the influence of these different factors on 
macrophage phenotype and function. 
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6. Abbreviations 
AICD  activation induced cell death 
AIDS  acquired immunodeficiency syndrome 
BLT  bone marrow liver thymus 
ca  cell-free 
cf  cell-associated 
CFSE  carboxy fluorescein succinimidyl ester 
cfu  colony forming units 
clodrolip clodronate liposomes 
CTLA  cytotoxic T lymphocyte antigen 
DAPI  diamidino-phenylindol 
DC  dendritic cell 
DNA  desoxyribonucleic acid 
DSS  dextran sodium sulphate 
ELISA  enzyme linked immunosorbent assay 
EndoCAb endotoxin core antibody 
EU  endotoxin unit 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FITC  fluoresceinisothyocyanate 
GALT  gut associated lymphoid tissue 
gp  glycoprotein 
Gy  gray 
HAART highly active antiretroviral therapy 
H&E  hematoxylin and eosin 
HIV  human immunodeficiency virus 
IEL  intraepithelial lymphocyte 
IL  interleukin 
IFN  interferon 
LBP  LPS binding protein 
LI  large intestine 
LPL  lamina propria lymphocyte 
LPS  lipopolysaccharide 
MACS  magnetic cell separation 
MFI  mean fluorescence intensity 
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MHC  major histocompatibility complex 
MLN  mesenteric lymph node 
NK cell natural killer cell 
NOD  non obese diabetic 
NOG  NOD/SCID ?c-/- 
PBL  peripheral blood leukocytes 
PBMC  peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PHA  phytohemagglutinin 
RAG  recombinase activating gene 
RLU  relative light units 
RNA  ribonucleic acid 
RT-PCR reverse transcription-polymerase chain reaction 
sCD14  soluble CD14 
SCID  severe combined immunodeficiency 
SD  standard deviation 
SI  small intestine 
SIV  simian immunodeficiency virus 
SP  seminal plasma 
SSC  side scatter 
STAT  signal transducer and activator 
TCID50 tissue culture infectious dose 50 
thy/li  thymus/liver 
TLR  toll like receptor 
TNF  tumor necrosis factor 
Treg  T regulatory cell 
WT  wild type 
?c  common gamma chain 
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